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ABSTRACT
Pre-Exposure Prophylaxis (PrEP) is any medical or public health procedure used be-
fore exposure to the disease causing agent, its purpose is to prevent, rather than treat
or cure a disease. Most commonly, PrEP refers to an experimental HIV-prevention
strategy that would use antiretrovirals to protect HIV-negative people from HIV in-
fection. A deterministic mathematical model of HIV transmission is developed to
evaluate the public-health impact of oral PrEP interventions, and to compare PrEP
effectiveness with respect to different evaluation methods. The effects of demographic,
behavioral, and epidemic parameters on the PrEP impact are studied in a multivari-
ate sensitivity analysis. Most of the published models on HIV intervention impact
assume that the number of individuals joining the sexually active population per
year is constant or proportional to the total population. In the second part of this
study, three models are presented and analyzed to study the PrEP intervention, with
constant, linear, and logistic recruitment rates. How different demographic assump-
tions can affect the evaluation of PrEP is studied. When provided with data, often
least square fitting or similar approaches can be used to determine a single set of ap-
proximated parameter values that make the model fit the data best. However, least
square fitting only provides point estimates and does not provide information on how
strongly the data supports these particular estimates. Therefore, in the third part of
this study, Bayesian parameter estimation is applied on fitting ODE model to the re-
lated HIV data. Starting with a set of prior distributions for the parameters as initial
guess, Bayes’ formula can be applied to obtain a set of posterior distributions for the
parameters which makes the model fit the observed data best. Evaluating the poste-
rior distribution often requires the integration of high-dimensional functions, which is
usually difficult to calculate numerically. Therefore, the Markov chain Monte Carlo
(MCMC) method is used to approximate the posterior distribution.
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Chapter 1
INTRODUCTION
Mathematical models have been used extensively to simulate HIV transmission
and to study the use of male circumcision, antiretroviral therapy (ART), microbicides,
and pre-exposure prophylaxis (PrEP) for HIV prevention. My study will focus on
PrEP for HIV prevention.
PrEP is any medical or public health procedure used before exposure to the dis-
ease causing agent, its purpose is to prevent, rather than treat or cure a disease
(such as malaria, and HIV). PrEP can also refer to the aggressive use of vaccination
(such as for rabies). Most commonly, PrEP refers to an experimental HIV-prevention
strategy that would use antiretrovirals to protect HIV-negative people from HIV in-
fection. With an estimated 39.5 million people living with HIV worldwide and 4.3
million new infections per year (UNAIDS (2013)), many people are at risk for HIV
infection through sexual transmission. Therefore preemptive measures must be taken
to prevent further dissemination. PrEP provides a promising prevention strategy for
further HIV transmission.
In 2010, evidence from two different randomized clinical trials (Grant et al. (2010);
Karim et al. (2010)) suggested that PrEP products based on antiretroviral drug Teno-
fovir taken orally as a pill (oral PrEP) or applied topically in the form of gel (vaginal
microbicides (VMB)) can help prevent HIV. First in South Africa, the CAPRISA
004 trial demonstrated a 39% (95%CI, 6% to 60%) overall decrease in HIV incidence
among women in the VMB (gel) arm of the trial who were advised to use the product
before and after each sex act (Karim et al. (2010)). Later, the Global iPrEx trial
of a daily use of a combination of two oral antiretroviral drugs, emtricitabine and
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tenofovir disoproxil fumarate, demonstrated a 44% efficacy (95%CI, 15% to 63%) re-
duction in the incidence of HIV, among men-who-have sex with men (MSM) (Grant
et al. (2010)).
The search for a safe and effective HIV vaccine is still ongoing. There is no HIV
vaccine and it is not expected in a near future, which makes the study of PrEP
important and practical. In 2012, one product (oral Truvada) was approved for PrEP
use by FDA in United States, and recommended for use in South Africa. And there
has been a broad discussion on what will be population-level benefits from wide-scale
PrEP use in high prevalence settings.
Mathematical models have been used to simulate HIV transmission and to study
the use of chemoprophylaxis among MSM (Desai et al. (2008); Supervie et al. (2010)).
Deterministic mathematical models of HIV heterosexual transmission stratified by
gender have been analyzed in Abbas et al. (2007); Dimitrov et al. (2011, 2010); Pre-
torius et al. (2010); Vissers et al. (2008); Wilson et al. (2008). Often a single inter-
vention outcome based on cumulative number or fractions of infections prevented,
on reduction in HIV prevalence or incidence has been used to evaluate the effective-
ness of PrEP interventions. These indicators express a wide variation over time and
often disagree in their forecast on the success of the intervention (Dimitrov et al.
(2010); Pretorius et al. (2010)). Therefore, the conclusions of many modeling studies
are significantly influenced by the choice of the evaluation method and the period of
evaluation. In particular, it has been pointed out that indicators based on prevented
infections tend to show mixed results over time due to their sensitivity to changes in
population dynamics (Dimitrov et al. (2011)).
In the first part of my study (Zhao et al. (2013)), I develop a deterministic mathe-
matical model of HIV transmission to evaluate the public-health impact of oral PrEP
interventions, compare PrEP effectiveness with respect to different evaluation meth-
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ods, and analyze its dynamics over time. Four traditional evaluation methods are
compared, including relative reduction in HIV prevalence and incidence which avoid
the ambiguity associated with commonly used indicators based on the absolute num-
ber of prevented infections. Two additional methods are considered which estimate
the burden of the epidemic to the public-health system. I then investigate the short
term and long term behavior of these indicators and the effects of key parameters on
the expected benefits from PrEP use. The effects of demographic, behavioral, and
epidemic parameters on the PrEP impact are studied in a multivariate sensitivity
analysis.
Since HIV is acquired predominately through sexual contacts, it is usually mod-
eled as a sexually transmitted disease, ignoring the other routes of transmission. In
this study, sexually active heterosexual population aged from 15 to 49 year are con-
sidered, as assumed in many published papers. Most of the published models on
HIV intervention impact I found assume that the number of individuals joining the
sexually active population per year is constant (constant entrance) or proportional
to the total population (linear entrance). In sexually active population with no mi-
gration, constant entrance implies that the same number of people reaches sexual
maturity annually. This may be an acceptable approximation over some short time
period, but not reasonable as the simulation period increases. The progression of
HIV infection from acquisition to symptoms of AIDS and then death is incredibly
slow compared with many other fatal diseases, and it can be further delayed by ART.
Therefore, a meaningful impact of prevention intervention should be expected over
several decades, which explains simulation periods of 20-50 years used in mathemat-
ical models. In the second part of this study, I will present and analyze three models
to study the PrEP intervention, with constant, linear, and logistic recruitment rates.
Except the recruitment rate, all the assumptions for the three models stay the same.
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How different demographic assumptions can affect the evaluation of PrEP will be
studied.
In the third part of this study, I will apply Bayesian inference on parameter
estimation on the basic HIV model without PrEP intervention. The least square
fitting (or similar approaches) only gives a single set of approximated parameter values
that make the model fit the data best. It only provides point estimates and does not
provide information on how strongly the data supports these particular estimates.
Therefore, a second approach I will try is the Bayesian parameter estimation on
fitting ODE model to the related HIV data. Starting with a set of prior distributions
for the parameters as initial guess, we can apply Bayes’ formula to obtain a set of
posterior distributions for the parameters which make the model fit the observed data
best. The posterior distributions provide the probability for each parameter to equal
any possible value.
4
Chapter 2
EFFECTIVENESS INDICATORS FOR HIV INTERVENTIONS
Details of the work in this section can be found in Zhao et al. (2013).
2.1 Model Description
Figure 2.1: Flow diagram of a PrEP intervention for the model (1) formulation.
In my models (see Figure 2.1) the population is divided into two major classes,
PrEP users (superscript p, Sp + Ip) and those that do not use PrEP (S + I), and
further stratified according to their HIV status into susceptible (S, Sp) and infected
(I, Ip). Individuals who develop AIDS are accumulated in non-sexually active class
A. Individuals join the community (reaching sexual maturity) and departure from
the sexually active population at constant rates (Λ, µ). A proportion k of the new
recruits start using PrEP. PrEP users are assumed to strictly follow the prescribed
regimens. The model which assumes that PrEP reduces both susceptibility and infec-
tiousness of the users (“dual-protection” model) is formulated by the following system
of differential equations:
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dSp
dt
= kΛ− (1− αs)β SpIN − (1− αs)(1− αi)β I
pSp
N
− µSp
dS
dt
= (1− k)Λ− β IS
N
− (1− αi)β IpSN − µS
dIp
dt
= (1− αs)β ISpN + (1− αs)(1− αi)β I
pSp
N
− (µ+ d)Ip
dI
dt
= β IS
N
+ (1− αi)β IpSN − (µ+ d)I.
(2.1)
Table 2.1: Parameter description and baseline values
Par. Description Value Ref.
d HIV carrier’s annual rate of progression to AIDS 0.1302 fitted sta (2012)
Λ Annual rate at which individuals 38094 calc. sta (2012)
become sexually active
1
µ Time (in years) to remain sexually active
1
0.0250 fitted sta (2012)
ba HIV acquisition risk per act 0.0030 fitted sta (2012)
n Number of sexual acts per year per individual 65.8494 fitted sta (2012)
β Cumulative HIV-acquisition risk β(n, ba) calc.
N(0) Initial sexually active population 106 assumed
P Initial HIV prevalence 0.166 sta (2012)
k1 Initial PrEP coverage 0.2 assumed
θ Reduction in the initial fraction of HIV positive 0.5 assumed
individuals as a result of pre-enrollment screening
k Proportion of the new recruits k = k1 assumed
that start using PrEP
αs Efficacy of PrEP in 0.5 assumed
reducing susceptibility of PrEP users
αi Efficacy of PrEP in 0.5 assumed
reducing infectiousness of PrEP users
6
Since the differential equations for these four compartments are independent from
the AIDS class (A), it is not included in the ODE system. Here N = Sp + S +
Ip + I represents the sexually active population and αs (αi) measures the efficacy of
PrEP in reducing susceptibility (infectiousness) of PrEP users. The cumulative HIV
acquisition risk per year β is calculated based on the HIV risk per act (ba) with a
HIV-positive partner and the average number of sex acts per year (n):
β = 1− (1− ba)n.
Cumulative acquisition risk (β) is an increasing function with respect to HIV-
acquisition risk per act ba and average number of sexual acts per year n.
PrEP is introduced at time (t = 0) in a population with N(0) = 1, 000, 000 and
HIV-prevalence (P ). It is assumed that PrEP is initially adopted by a fraction k1 of
the individuals and that the initial fraction of HIV-positive individuals is reduced by
θ as a result of pre-enrollment HIV screening:
Sp(0) = k1(1− P )N(0)
S(0) = (1− k1)(1− P )N(0)
Ip(0) = (1− θ)k1PN(0)
I(0) = (1− (1− θ)k1)PN(0),
The initial distribution of the epidemic classes may not be critical for the asymp-
totic behavior of the system but it is essential for the impact indicators calculated
over fixed periods of time after the start of the intervention. To isolate the impact of
the choice of the evaluation method I simplify the intervention schedule and assume
instantaneous uptake of PrEP at predetermined level (k = k1).
Clinical trials in HIV prevention are usually designed to evaluate the efficacy of
the tested products in reducing susceptibility (αs) only. Although a reduction in
7
infectiousness (αi) is plausible it is not verifiable since all HIV positive participants
are immediately withdrawn from the product. Moreover, the biomedical products
currently in testing, are based on antiretroviral drugs and are not recommended for
use by infected individuals due to the risk of drug resistance development. Therefore,
the majority of the modelers assume uni-directional PrEP protection (αi = 0) which
means that using PrEP has no effect on the infectiousness or that infected individuals
do not take PrEP anymore. This scenario may also represent the idea of control of
the PrEP usage by the HIV-positive individuals since fast removal of the infected
users from PrEP is the equivalent of setting αi = 0. To address that possibility I
consider a “single-protection” model in which the variable Ip is removed from the
baseline model as follows:
dSp
dt
= kΛ− (1− αs)β SpIN − µSp
dS
dt
= (1− k)Λ− β SI
N
− µS
dI
dt
= β SI
N
+ (1− αs)β SpIN − (µ+ d)I
(2.2)
with initial conditions:
Sp(0) = k1(1− P )N(0)
S(0) = (1− k1)(1− P )N(0)
I(0) = PN(0).
In my analysis HIV epidemics are simulated in presence and in absence of PrEP. If
PrEP is not available the “no intervention” model is reduced to the following system:
dS
dt
= Λ− β SI
N
− µS
dI
dt
= β SI
N
− (µ+ d)I
(2.3)
with S(0) = (1− P )N(0) and I(0) = PN(0).
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2.1.1 Modeling Assumptions
Several important assumptions are incorporated into the model:
• The HIV prevalence in the whole population is representative for the HIV preva-
lence among each gender, i.e., the chance to have a HIV-positive partner is pro-
portional to the total HIV prevalence. Transmission and susceptibility do not
differ between the sexes, either with or without PrEP.
• Individuals are assumed to have a fixed number of sex acts per year.
• Sexual behavior of an individual does not change if he/she starts using PrEP
but sexual activity stops once AIDS is developed.
• The use of PrEP reduces both HIV susceptibility and infectiousness (indepen-
dently) and by this reduces the HIV acquisition risk per sex act.
• Perfect adherence to PrEP is assumed: individuals who start using PrEP con-
tinue to follow the prescribed regimen indefinitely. However, the scenario with
no reduction of infectiousness due to PrEP (αi = 0) is equivalent to immediate
withdrawal from PrEP after HIV acquisition.
• The use of other HIV prevention measures including condom use, male circum-
cision, and ARV treatments are not considered separately in my model. Their
effects on HIV transmission are aggregated in the HIV acquisition risk per act.
2.1.2 Model Parametrization
To parameterize the model in the scenario without PrEP, I used demographic and
HIV prevalence data representative for the sexually active population (15-49 years
9
old) in South Africa for the period between 2001 and 2011 provided by the Statistical
Institute of South Africa (sta (2012)) .
First, I estimate the recruitment rate in the sexually active population (Λ). Calcu-
lations are based on the approximated number of 15-year olds (population aged 15 to 19
5
=
5175400
5
= 1035100) and the total population size (27,172,400) aged 15 to 49 , in year
2011. In the model without PrEP, initial total sexually active population is assumed
to be N = 106. Therefore, I scale the estimated entrance rate to obtain the recruit-
ment of the sexually active population (Λ) in the model: Λ = 106 · 1035100
27172400
≈ 38094
which willed be used in the epidemic simulations.
Next, I fit the projected HIV prevalence I
S+I
by the model without PrEP to the
2001-2011 prevalence data from South Africa (sta (2012)). I use the Matlab built-
in function ‘fminsearch’ to do the data fitting, with error measurement
∑n
i=1 |psi−pi|
n
,
where psi represents the HIV prevalence from model simulation, pi represents the
HIV prevalence from data, and n represents the number of data points. Starting with
initial parameter values borrowed from published studies: ba = 0.0038(Boily et al.
(2009)), n = 80(Kalichman et al. (2009); Wawer et al. (2005)), µ = 1/35(UNAIDS
(2009)), and d = 1/10(Morgan et al. (2002); Porter and Zaba (2004)), I obtain the
following parameter set which fits best the prevalence data from year 2001 to year
2011: ba = 0.0030, n = 65.8494, µ = 0.0250, and d = 0.1302 (with error of data
fitting=0.0737). Figure 2.2 shows the HIV prevalence data and the best-fitting es-
timates obtained by the “no intervention” model for the period 2001-2011 (Figure
2.2(a)) as well as its long-term projections (Figure 2.2(b)).
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Figure 2.2: (a) HIV prevalence among sexually active population in South Africa
for the period 2001- 2011 from data and fitted with the “no intervention” model; (b)
Long-term projections of the HIV prevalence based on fitted “no intervention” model.
2.2 Effectiveness Indicators
The impact of PrEP in my analysis is evaluated by the quantitative indicators
described in Table 2.2. The first four indicators are widely used in modeling studies
to evaluate the impact of interventions over fixed periods [0, T ]. The cumulative and
the fractional indicators measure the intervention effectiveness based on the infections
prevented in scenarios with PrEP compared to scenarios without PrEP. The preva-
lence and incidence indicators measure the reduction of the projected HIV prevalence
and incidence due to PrEP. I propose the last two evaluation methods based on the
reduction of the number of infected individuals as they are closely related to the eco-
nomic burden of the HIV epidemic on the public health system at community and
state level since the money allocated for HIV treatment is proportional to the size of
the infected population.
Predictions of mathematical models based on quantitative indicators are often
11
Table 2.2: Indicator description
Indicator Name Description
CI(T ) Cumulative indicator Cumulative number of infections prevented
over the period [0, T ] due to the usage of PrEP
FI(T ) Fractional indicator Fraction of infections prevented
over the period [0, T ] due to the usage of PrEP
PI(T ) Prevalence indicator Reduction in HIV-prevalence
at time t = T due to the usage of PrEP
aII(T ) Incidence indicator Reduction in the annual HIV incidence
at time t = T due to the usage of PrEP
CˆI(T ) Reduction indicator Reduction in the projected number of infections
at time t = T due to the usage of PrEP
FˆI(T ) Fractional reduction Fraction of the number of infections reduced
indicator at time t = T reduced due to the usage of PrEP
used to estimate the effectiveness of novel interventions and to compare the expected
benefits from different prevention options. The analytical conclusions in favor of spe-
cific option are usually based on evaluations of the indicators over a few fixed periods
of intervention time, most likely 10 years but almost certainly between 5 and 30 years.
However, all indicators vary over time and may express different preferences when used
to decide between comparable prevention programs. The idea is illustrated with a
comparison of the indicator dynamics for two hypothetical PrEP interventions. Inter-
vention 1 assumes no control of the PrEP use by HIV-positive individuals (θ = 0) and
50% PrEP efficacy in reducing both susceptibility and infectiousness (αs = αi = 0.5)
while Intervention 2 requires a negative HIV test as a condition for prescribing PrEP
12
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Figure 2.3: Comparison of the indicators projections for two PrEP interventions over
50-year period. Intervention 1 assumes that θ = 0 and αs = αi = 0.5. Intervention 2
assumes that θ = 1, αs = 0.5 and αi = 0.9. All other parameters are fixed on their
baseline parameter values from Table 2.1.
(θ = 1) and better PrEP efficacy in reducing infectiousness (αs = 0.5, αi = 0.9). Each
of the incidence, prevalence and fractional indicators shows increasing effectiveness
of both interventions over 50 years after initiation of PrEP (Figure 2.3) with more
benefits attributed to Intervention 1 initially but higher impact of Intervention 2 in a
long-term. However, they disagree on the timing when the advantage of Intervention
1 ends. For instance, a preference to Intervention 2 is given after 17 years of PrEP
use if based on reduction in HIV incidence and after 22 years if based on reduction
in HIV prevalence. The public-health impact of Intervention 1 measured in terms of
cumulative fraction of prevented infections remains higher compared to Intervention
2 for up to 32 years which is substantially longer than the evaluation periods used
in the majority of the quantitative analyses. Therefore, if PrEP is evaluated over
periods between 17 and 32 years the choice of quantitative indicator is critical. Now
take a closer look at the key drivers of those discrepancies in the indicators’ dynamics.
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2.2.1 Indicator Expressions
To utilize the calculation of the cumulative indicators it is necessary to keep track
of the cumulative number of new infections. For this reason I add two equations to
the “dual-protection” model (2.1):
d(IpNew)
dt
= (1− αs)β SpIN + (1− αs)(1− αi)β S
pIp
N
d(INew)
dt
= β SI
N
+ (1− αi)β SIpN ,
(2.4)
and add an equation to the “single-protection” model (2.2):
d(INew)
dt
= β SI
N
+ (1− αs)β SpIN (2.5)
with initial conditions INew(0) = I
p
New(0) = 0, and INew(0) = 0 respectively. These
new variables (IpNew and INew) represent cumulative HIV infections in PrEP users and
non-users, respectively.
If PrEP is not available, the “no intervention” model becomes:
dS
dt
= Λ− β SI
N
− µS
dI
dt
= β SI
N
− (µ+ d)I
d(INew)
dt
= β SI
N
(2.6)
with initial conditions S(0) = (1− P )N(0), I(0) = PN(0), and INew(0) = 0.
I proceed with analysis of the behavior of the indicators assuming “dual pro-
tection”. [ ] is used to denote variables from the model without PrEP (2.6) and
[ ]DP for variables from the “dual-protection” model with PrEP (2.4). Using these
notations, the qualitative indicators have the following expressions:
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CI(T ) =
∫ T
0
([ d
dt
INew(t)]− [ ddtIpNew(t) + ddtINew(t)]DP )dt
FI(T ) =
∫ T
0 ([
d
dt
INew(t)]−[ ddt I
p
New(t)+
d
dt
INew(t)]DP )dt∫ T
0 [
d
dt
INew(t)]dt
PI(T ) = 1− [
Ip(T )+I(T )
Sp(T )+S(T )+Ip(T )+I(T )
]DP
[
I(T )
S(T )+I(T )
]
aII(T ) = 1− [
∫T+1
T
[ d
dt
I
p
New
(t)+ d
dt
INew(t)]dt
Sp(T )+S(T )
]DP
[
∫T+1
T
d
dt
INew(t)dt
S(T )
]
CˆI(T ) = [I(T )]− [Ip(T ) + I(T )]DP
FˆI(T ) =
[I(T )]−[Ip(T )+I(T )]DP
[I(T )]
= 1− [Ip(T )+I(T )]DP
[I(T )]
.
Since integral evaluated on derivative function can be simplified, previous expres-
sions of the indicators are equivalent to the following:
CI(T ) = [INew(T )]− [IpNew(T ) + INew(T )]DP
FI(T ) =
[INew(T )]−[IpNew(T )+INew(T )]DP
[INew(T )]
= 1− [I
p
New(T )+INew(T )]DP
[INew(T )]
PI(T ) = 1− [
Ip(T )+I(T )
Sp(T )+S(T )+Ip(T )+I(T )
]DP
[
I(T )
S(T )+I(T )
]
aII(T ) = 1− [
I
p
New
(T+1)+INew(T+1)−(I
p
New
(T )+INew(T ))
Sp(T )+S(T )
]DP
[
INew(T+1)−INew(T )
S(T )
]
CˆI(T ) = [I(T )]− [Ip(T ) + I(T )]DP
FˆI(T ) =
[I(T )]−[Ip(T )+I(T )]DP
[I(T )]
= 1− [Ip(T )+I(T )]DP
[I(T )]
.
From these expressions it can be seen that the indicators FI , PI , aII , FI and FˆI
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are dimensionless and do not depend on the population size. The other two indicators
CI and CˆI measure changes in population group sizes, and are not dimensionless.
2.2.2 Initial Dynamics of the Indicators
To understand the practical value of the qualitative indicators I examine their
short, intermediate and long term dynamics. I begin with indicator approximations
shortly after the start of the intervention. Using the initial conditions defined above,
the following expressions associated with the initial indicators’ behavior are obtained
(details can be found in the Appendix of Zhao et al. (2013)):
CI ≈ [αs + (1− θ)αi(1− αsk1)]k1βP (1− P )N(0)dt
FI ≈ [αs + (1− θ)αi(1− αsk1)]k1
PI ≈ [αs + (1− θ)αi(1− αsk1)]k1β(1− P )dt
aII ≈ (1− αsk1)[1− (1− θ)αik1]{1− (1− αsk1)k1[1− (1− θ)αik1]}k1βPdt
CˆI ≈ [αs + (1− θ)αi(1− αsk1)]k1βP (1− P )N(0)dt
FˆI ≈ [αs + (1− θ)αi(1− αsk1)]k1β(1− P )dt.
Here I assume dt = 1 for the approximation for aII because the definition of the
incidence indicator is on annual basis.
Note that the expression for the fractional indicator (FI) depends only on the
PrEP efficacy (αs, αi) and factors related to the implementation of the intervention
at its start such as initial coverage (k1) and the introductory control of the PrEP usage
by HIV-positive individuals (θ) but not on the demographic, behavioral and epidemic
parameters. Therefore, fractional indicator represents a metric of the “immediate
impact of PrEP” on the HIV epidemic, which is independent of the specific population
and the status of the HIV epidemic in it. This metric accounts for the effects of the
reduced susceptibility (αs) of the fraction k1 of the population which initially uses
PrEP combined with the reduced infectiousness (αi) of a limited fraction (1− θ)k1 of
16
the infected population when in contact with partners unprotected by PrEP (1−αsk1).
Clearly, if PrEP provides uni-directional protection (αi = 0) or none of the infected
individuals is using PrEP (θ = 1) then the “immediate impact of PrEP” is given by
the product of PrEP efficacy and coverage (αsk1). The initial behavior of all other
indicators depend on the HIV prevalence (P ) at the time of PrEP introduction as well
as on the cumulative HIV-acquisition risk (β). Moreover, the cumulative (CI) and
reduction (CˆI) indicators also depend on the initial population size (N(0)), which is
consistent with the fact that only indicators CI and CˆI measure changes on population
group sizes, and are not dimensionless.
The initial rate of change of the indicators can be approximated as:
CI
′ ≈ [αs + (1− θ)αi(1− αsk1)]k1βP (1− P )N(0)
PI
′ ≈ [αs + (1− θ)αi(1− αsk1)]k1β(1− P )
aII
′ ≈ (1− αsk1)[1− (1− θ)αik1]{1− (1− αsk1)k1[1− (1− θ)αik1]}k1βP
CˆI
′
≈ [αs + (1− θ)αi(1− αsk1)]k1βP (1− P )N(0)
FˆI
′
≈ [αs + (1− θ)αi(1− αsk1)]k1β(1− P ).
Notice that initially CI
′ ≈ CˆI
′
and PI
′ ≈ FˆI
′
. Now study the sensitivity of
the initial rate of change of the reduction indicators (CˆI and FˆI) to some of the
intervention (θ, k1) and epidemic (P ) parameters by bifurcation simulations (Figure
2.4). These bifurcation parameters were chosen because they are easier to evaluate at
community levels compared to HIV-acquisition risk and PrEP efficacy. The graphs in
Figure 2.4, (a) and (b) demonstrate that the growth of both indicators accelerates if
more people start on PrEP (larger k1) but decelerates if the control of the PrEP usage
by infected individuals is more effective (larger θ). The initial rate of change is more
sensitive to k1 than to θ but it is clear that the growth rate of both indicators at the
time of PrEP introduction expresses qualitatively similar behavior with respect to the
intervention parameters (θ, k1). In contrast, the graphs presenting the dependence
17
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Figure 2.4: Initial growth rate of reduction (CˆI) and fractional reduction (FˆI) indica-
tors with respect to θ, k1 and P . CˆI is denoted by green solid line, while FˆI is denoted
by blue dashed line. All other parameters are fixed on their baseline parameter values
from Table 2.1.
on the initial HIV prevalence show serious discrepancies (Figure 2.4(c)). The initial
growth rate of the reduction indicator (CˆI) increases when the HIV prevalence ranges
from 0 to 50% which includes all realistic values observed so far, particularly in Sub-
Saharan Africa (Figure 2.4(c)). In comparison, the increase in HIV prevalence within
the same range implies smaller growth rate of the fractional reduction indicator FˆI .
2.2.3 Asymptotic Behavior of the Indicators
In resource-constrained settings, it is unrealistic to expect the HIV epidemic will
die out without additional intervention. Therefore, in the following, I assume that
the basic reproduction number of the “no intervention” model is R0 =
β
µ+d
> 1. The
asymptotic HIV prevalence in this case is given by: [ I
S+I
] = 1− µ+d
β
= 1− 1
R0
.
I want to point out that if the PrEP intervention is strong enough to cause the
eradication of HIV in the population, i.e., the HIV epidemic approaches the disease-
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free equilibrium with the “dual-protection” model, then the asymptotic behavior of
all indicators is well determined: i) the cumulative indicator will grow to infinity; ii)
the reduction indicator will stabilize at [I] = R0−1
β−d Λ; and iii) all other indicators will
approach one. Unfortunately, PrEP intervention alone is unlikely to be sufficient to
eradicate HIV. In that case it is shown that the asymptotic behavior of the indica-
tors can be expressed in terms of the asymptotic proportion (p) of the HIV-positive
subpopulation which have been infected while using PrEP (details are presented in
Appendix of Zhao et al. (2013)), where p is defined as follows:
p = [
Ip
Ip + I
]DP .
Expressions for the asymptotic values of four of the indicators:
PI = 1−
R0− 1−αs(1−p)(1−αs)(1−αip)
R0−1
aII = 1− R0
(1−αs)(1−αip)
1−αs(1−p) −1
R0−1
CˆI = [
R0−1
β−d − R0(1−αip)(1−αsk)−1β(1−αip)(1−αsp)−d ]Λ
FˆI = 1− R0(1−αip)(1−αsk)−1R0−1
β−d
β(1−αip)(1−αsp)−d
and the asymptotic rate of growth of the cumulative indicator:
CI
′ = (µ+ d)[R0−1
β−d − R0(1−αip)(1−αsk)−1β(1−αip)(1−αsp)−d ]Λ = (µ+ d)CˆI .
show that they are independent of the initial HIV prevalence (P ) and the initial
control on the PrEP use by HIV-positive individuals (θ) which have been of critical
importance for the initial dynamics of the indicators. Cumulative indicators (CˆI and
CI) depend indirectly on the population size (N) which determines the entry rate in
the population (Λ). Notice that CI
′ = (µ+d)CˆI so the value of the reduction indicator
is proportional to the annual number of new infections prevented due to PrEP use in
the long term. The rest of the indicators are not influenced by the population size
(N). Although recruitment parameters such as k and Λ are not explicitly present in
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Figure 2.5: (a) Asymptotic values of the proportion of the HIV-positive individuals
who have been infected while using PrEP (p) as a function of the PrEP efficacies
(αs and αi) assuming 10 % PrEP coverage (k = k1 = 0.1). (b) Long term dynamics
of the quantitative indicators based on simulations with “dual-protection” and “no
intervention” models using parameters from Table 2.1.
some of the expressions above they may affect the asymptotic proportion of PrEP
users among infected sub-population (p).
Because of the algebraic complexity, I can not explicitly express p. Therefore, a
good approximation of p is important for the evaluation of the asymptotic levels of
the indicators.
Now study the variation of p when the reduction in susceptibility and infectious-
ness range from 0 to 100 % (Figure 2.5(a)) for intervention coverage (k = 0.1) which
is not sufficient to eradicate HIV even if the PrEP protection against HIV is perfect
(αs = αi = 1). It shows that p depends greatly on the reduction in susceptibility
(αs) and very little on the reduction in infectiousness (αi). It is clear that the frac-
tion of infections which occur when using PrEP (p) ranges from zero, in case that
PrEP provides complete protection against HIV (αs = 1) and no PrEP users ever
20
get infected, to the level of the PrEP coverage (k) in case that PrEP is completely
ineffective (αs = 0) and infections are proportionally distributed among PrEP users
and non-users.
The next goal is to examine and compare the long-term behavior of the indicators
(specifically those expressed as ratios) for a fixed PrEP intervention (Figure 2.5(b)).
Although qualitatively similar the trajectories of the indicators show some important
differences. First, some indicators such as the reduction in HIV prevalence and the
reduction in the infected fraction start at zero while others such as the fraction of
prevented infections and the reduction in HIV incidence initiate at positive values.
Therefore, it is not surprising that the indicators reach a specific threshold of 20% at
times varying from 3 to 11 years after the introduction of PrEP. The times needed
to report 50% effectiveness are even farther apart. It takes the intervention 24 years
and 33 years to reduce in half the expected HIV incidence and HIV prevalence, re-
spectively. However, almost 90 years are necessary to reduce the cumulative number
of new infections by 50%, i.e., such reduction is infeasible over traditionally used
evaluation periods of up to 30 years.
2.2.4 Evaluation of the Public-health Impact of PrEP
The initial and asymptotic behavior of the indicators are useful in understanding
what drives the observed differences in their projections. However, from a public
health perspective it is more important to analyze the indicators values over more
practical time intervals. Although no fixed standards exist, the majority of the quan-
titative studies assume that preventive interventions are implemented for 10 years
when their effectiveness is evaluated. The same period is recommended by the World
Health Organizations as an evaluation period when cost-effectiveness analyses are
conducted (Edejer (2003)). Longer periods are investigated in few studies but always
21
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Figure 2.6: Contour plots of the indicators (FI , PI , and aII) over 10 and 30 years
with respect to selected intervention parameters αi and αs. All other parameters are
fixed at the baseline parameter values from Table 2.1.
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Figure 2.7: Contour plots of the indicators (FI , PI , and aII) over 10 and 30 years
with respect to selected epidemic parameters β and k1. All other parameters are fixed
at the baseline parameter values from Table 2.1.
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up to 30 years.
In this section it is explored the dependence of the indicator readings over 10 and
30 years on key epidemic and intervention parameters. Clearly, the impact of PrEP
is positively correlated with both reductions in susceptibility (αs) and infectiousness
(αi) regardless of what indicator is used to quantify it (Figure 2.6). The slopes of
the contour plots in the PrEP efficacy parameter space show that if the susceptibility
efficacy(αs) is relatively low (up to 30 %) all indicators are equally dependent of
both αs and αi. However, with the increase of the PrEP protection against HIV the
influence of the reduction of infectiousness decreases significantly. The prevalence
indicator (PI) projects the least effectiveness over 10 years of PrEP use. It predicts
that more than 70 % and 55% PrEP efficacy is needed to achieve 20% reduction in HIV
prevalence with uni-directional (αi = 0) and bi-directional (αi = αs) interventions,
respectively. In comparison, 20% reduction in the expected HIV infections is possible
with 65% effective uni-directional and 55% bi-directional PrEP while 20% reduction
in HIV incidence is feasible even if less than 45% effective uni-directional and 30%
bi-directional PrEP is used over 10 years. The order of predicted effectiveness by the
prevalence and the fractional indicators is reversed over an evaluation period of 30
years. More than half of the parameter space results in more than 50% reduction in
HIV prevalence (PI), an unreachable threshold as a reduction in expected infections
(FI).
All indicators increase with coverage k = k1 (Figure 2.7). The prevalence and
fractional indicators are more sensitive to changes in the transmission rate (β) than
is the annual incidence indicator, with increasing influence of β on the fraction of
prevented infection for larger evaluation periods. The maximum PrEP effectiveness
over 10 years of PrEP use is predicted for complete coverage (k) and modest level of
the transmission rate (β) while over 30 years it is achieved for the lowest possible β.
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2.3 Sensitivity Analysis
Finally, it is explored the sensitivity of the indicators to changes in each param-
eter. Using the algorithm presented in Blower and Dowlatabadi (1994) I calculate
the Partial Rank Correlation Coefficients (PRCC) which evaluate the monotonicity
of the model outcomes (indicators) in terms of the model parameters. Values of
PRCC closer to ±1, imply stronger correlation between the output indicator and the
input parameter while the sign of the coefficients determines if the outcomes grow or
decrease with an increase of the input parameters.
I study separately the sensitivity of the indicators to the parameters (ba, n, µ, and
d) which are fitted using data from South Africa. In the analysis I choose 1000 random
parameters combinations of those input parameters sampled uniformly from their
corresponding ranges: [0.0015, 0.0045] for ba, [32.9247, 98.7741] for n, [0.0125, 0.0375]
for µ, and [0.0651, 0.1953] for d. Each range is chosen as [0.5, 1.5]∗(baseline parameter
value in Table 2.1). The rest of the parameters are fixed on their baseline values in
Table 2.1. For each parameter set I simulate the models with “dual-protection” and
no intervention and calculate PRCC matrix of all six indicators CI , FI , PI , aII , CˆI ,
and FˆI for the first 10 years (standard analysis) as well as for the 100 years (long-term
analysis). Similarly, I investigate the indicators’ sensitivity to the remaining epidemic
and intervention parameters (αs, αi, P , k1(k = k1), and θ), uniformly sampled from
their corresponding ranges: [0.25, 0.75] for αs, [0.25, 0.75] for αi, [0.083, 0.249] for P ,
[0.1, 0.3] for k1, and [0.25, 0.75] for θ. Results are presented in Figure 2.8.
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Figure 2.8: Partial rank correlation coefficients (PRCC) between model parameters
and the quantitative indicators over 10 and 100 years.
Correlations for 10-year intervention suggest that from the fitted parameters the
indicators are most sensitive to the factors (ba and n) which determine the trans-
mission rate β. However, their influence over time decreases. CI and CˆI are still
positively correlated to the two factors while the rest of the indicators are negatively
correlated to the two factors over 100 years, both dependencies are weak. The in-
tervention outcomes are split into two groups with respect to their correlation with
the HIV induced mortality (d): the cumulative indicators being negatively correlated
while the rest being positively correlated with d. Similar discrepancy is observed with
respect to the influence of the initial HIV prevalence P over 10 years but the corre-
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lations are reversed (positive - for the the cumulative indicators and negative for the
rest). Interestingly, in that case the difference between the indicators disappears in a
long term. Note that although P appears in the initial conditions only, it continues
to have strong influence on all the cumulative and reduction indicators for more than
10 years while its impact on the fraction of prevented infection gets even stronger
over time.
Among the intervention parameters, PrEP coverage (k) and PrEP efficacies per
act (αs and αi) express strong positive correlation with all the indicators in a short
term. It remains significant in a long term for all outcomes. This confirms that PrEP
coverage and protection level are critical to the intervention success regardless which
qualitative metric is used. In contrast, the influence of the initial control on the PrEP
use by HIV-positive individuals (θ) diminishes substantially in time.
The prevalence (PI) and the annual incidence (aII) indicators have almost the
same sensitivity to all parameters. Therefore they should have consistent projections
when evaluating the impact of the intervention.
2.4 Discussion
Precise evaluation of the expected public-health impact of biomedical interventions
for HIV preventions becomes increasingly important with more prevention options
entering the pipeline toward licensure. The practice shows that even if the products
are effective in reducing the individual risk of acquisition (individual efficacy) the
benefits from general usage (population effectiveness) may be limited by variety of
epidemic, behavioral and intervention factors.
It is demonstrated that the quantitative indicators have distinct dynamical pro-
file shortly after the start of PrEP intervention which modifies substantially over
time. As a result, when calculated over a fixed period of time these indicators may
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project significantly different PrEP effectiveness and therefore influence the decision
if particular products are potentially good enough for implementation. In general,
new prevention methods need to prove their effectiveness in randomized clinical trial
(RCT), i.e., to demonstrate that the observed efficacy is significantly larger than zero
(positive 95% confidence interval), before applying for licensure. In reality, developers
and public-health officials try to avoid PrEP products with low efficacy because the
controlled environments of the clinical trials are difficult to be replicated at commu-
nity level. Another concern is that the availability of PrEP may affect sexual behavior
and encourage risky sex practices. Therefore, minimal efficacy thresholds of 20% or
higher are often included in the design of RCTs and similar levels of effectiveness is
expected when interventions are modeled at population level (Dimitrov et al. (2013);
Grant et al. (2010)). Other studies imply that 50% biological efficacy is needed to
guarantee significant public-health impact. The question remains what does 20% or
50% PrEP effectiveness mean? It has been shown the widely used evaluation metrics
may disagree over practical intervals of time (Figure 2.5). A reduction in HIV inci-
dence at pre-specified levels seems most realistic as an intervention goal but it is not
easy to be estimated in the population. In contrast, a reduction in HIV prevalence is
easier to be recorded but more difficult to be achieved in a short term. The reduction
in the number of new HIV infections, which is the most popular public-health metric,
projects strong PrEP effectiveness initially but grows slower than the other indicators
over time.
Moreover, if used to compare the impact of PrEP interventions different indi-
cators may give preference to different options (Figure 2.3). Public-health officials
who consider PrEP to be integrated in HIV prevention programs should base their
decision on a complex of quantitative metrics. Although is specifically focused on
HIV prevention, the same theoretical approach may be extended to model other in-
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fectious diseases, such as malaria, cholera, and tuberculosis, or evaluate the impact
of interventions, such as male circumcision, vaccination or quarantine strategies.
Presented results, assuming perfect adherence and instantaneous uptake, are likely
to give optimistic views of the potential impact of a PrEP intervention. Although,
overall self-reported adherence in the concluded clinical trials is high it is unclear how
consistently PrEP will be used in real settings. Perfect adherence and other simpli-
fying assumptions allowed to support the observations on the indicators and their
simulated dynamics with analytical expressions which were easier to be interpreted.
I believe that more complex and realistic modeling setup will be more useful in pro-
jecting benefits due to PrEP use but it is unlikely to resolve the differences between
the interventional outcomes reported in this section.
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Chapter 3
DEMOGRAPHIC ENTRANCE RATES FOR MATHEMATICAL MODELING OF
HIV INTERVENTIONS
The most often mathematically modeled prevention interventions for HIV are male
circumcision, test and treat strategy as prevention, microbicides, and PrEP.
Three randomized controlled trials have shown that male circumcision reduces the
risk of heterosexually acquired HIV infection in men by approximately 60%. Male
circumcision for HIV prevention has been broadly modeled in heterosexual population
(Alsallaq et al. (2013, 2009); Andersson et al. (2011); Cox et al. (2011); Dushoff et al.
(2011); Hallett et al. (2008); Nagelkerke et al. (2007); Podder et al. (2007); Williams
et al. (2006)), and also has been modeled in male homosexual population(Londish
et al. (2010)).
Standard antiretroviral therapy (ART) consists of the combination of at least
three antiretroviral (ARV) drugs to suppress the HIV virus and stop the progression
of HIV disease. Besides individual-wise benefits, expanded access to ART can also
reduce the HIV transmission at population level antiretroviral, so treatment is also
considered as an HIV prevention strategy. Mathematical models have been used to
study antiretroviral therapy (Alsallaq et al. (2013); Cremin et al. (2013); Law et al.
(2001); Lima et al. (2008)), also to discuss treatment as prevention or ‘test and treat’
strategy (Andrews et al. (2012); Hallett et al. (2009); Sorensen et al. (2012)). Within
these papers, Granich et al. (2009); Wagner and Blower (2012) proposed that universal
test and treat of HIV may be used as a prevention method, and it may eliminate the
HIV.
Microbicides are compounds that can be applied inside the vagina or rectum to
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protect against sexually transmitted infections (STIs) including HIV. Many papers
have used mathematical models to study this HIV prevention method (Boily et al.
(2011); Breban et al. (2006); Cox et al. (2011); Dimitrov et al. (2010); Karmon et al.
(2003); Wilson et al. (2008)).
PrEP is a new HIV prevention method in which people who do not have HIV
infection take a pill daily to reduce their risk of becoming infected. Only people who
are HIV-negative should use PrEP. An HIV test is required before starting PrEP
and then every 3 months while taking PrEP. PrEP, although is a relatively new HIV
prevention method, has also been extensively mathematically modeled (Abbas et al.
(2007); Cremin et al. (2013); Desai et al. (2008); Dimitrov et al. (2012); Grant et al.
(2010); Juusola et al. (2012); Nichols et al. (2013); Supervie et al. (2011, 2010); Zhao
et al. (2013)).
Using related key words, I collected and screened papers from ‘Web of Knowl-
edge’ database and ‘PubMed’ database. For each related paper, I collect the infor-
mation about the population being modeled, recruitment mechanism, mechanisms of
departures from the population, assumptions regarding migration. The results are
summarized in Table B.1, B.2, and B.3.
As observed from this summary, models use different demographic assumptions on
the population entrance rate and departure rate. Models use either constant entrance
rate or linear entrance rate. Although logistic entrance rate has not been observed
in the collected published papers, I will include it in the main study to be compared
with constant and linear entrance rates. Population departure rates are assumed in
these papers, while most of the papers do not include the migration in their studies.
The following study will discuss the different assumptions on the population en-
trance rate, on the study of PrEP intervention. Except that no evidence shows that
PrEP reduces the infectiousness of HIV positive people, and I assume αi = 0, all the
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modeling assumptions will be the same as in section 2.1.1. And for briefness, I do
not present the details for model descriptions and parameterizations in this section,
which are similar to what have been done in section 2.1. Indicators are also defined
in the same way as in section 2.2.1.
3.1 Models without Intervention
First being studied is the impact of the assumptions about the recruitment rate
on the population dynamics in absence of PrEP.
dS
dt
= f(N)− β SI
N
− µS , P (S, I)
dI
dt
= β SI
N
− (µ+ d)I , Q(S, I).
(3.1)
with S(0) = (1 − P )N(0) and I(0) = PN(0), where P is the initial HIV prevalence
in the initial population of size N(0).
Here the total population N is divided into two major classes, susceptibles (S)
and infected (I). Frequency-dependent transmission is assumed and the cumulative
HIV acquisition risk per year β is calculated based on the HIV risk per act (βa) with
a HIV-positive partner and the average number of sex acts per year (n):
β = 1− (1− ba)n.
Individuals join the population (become sexually active) at rate f(N). Recruit-
ment formulations f(N) = Λ, f(N) = rN , and f(N) = rN(1− N
K
) will be explored,
corresponding to constant, proportional to size and logistic entrance rate, respectively.
All model parameters are described in Table 3.1.
3.1.1 Models with Constant Recruitment
In this section, it is assumed that f(N) = Λ in model (3.1).
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Table 3.1: Parameter description for models with different entrance rates
Par. Description
Λ Annual rate at which individuals become sexually active
r Growth rate at which individuals become sexually active
K Population carrying capacity
ba HIV acquisition risk per act
n Number of sexual acts per year per individual
β Cumulative HIV-acquisition risk(calculated from ba and n)
1
µ
Time (in years) to remain sexually active
d HIV carrier’s annual rate of progression to AIDS
k Proportion of the new recruits that start using PrEP
αs Efficacy of PrEP in reducing susceptibility of PrEP users
Proposition 3.1.1.1. With nonnegative initial conditions all solutions of model (3.1)
are nonnegative and bounded with total population size N(t) ≤ max{N(0), Λ
µ
}.
• When the basic reproduction number R0 = βµ+d < 1, model (3.1) has an unique
disease-free equilibrium E0 = (
1
µ
Λ, 0) which is (globally) stable.
• When R0 > 1, E0 is unstable and the model possesses an unique endemic equi-
librium E∗ = ( 1
β−dΛ,
1
(β−d) · (R0 − 1)Λ) which is (globally) stable.
Proof. Proof can be found in Appendix C. Also see Hwang and Kuang (2003).
3.1.2 Models with Linear Recruitment
In this section, it is assumed that f(N) = rN in model (3.1).
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Notice that
lim
(S,I)→(0,0)
SI
N
= lim
(S,I)→(0,0)
SI
S + I
= 0.
Thus it is defined that P (0, 0) = 0 and Q(0, 0) = 0. With this assumption, E = (0, 0)
is a unique steady state of (3.1), and both P (S, I) and Q(S, I) are continuous on
{(S, I)|S ≥ 0, I ≥ 0}.
Proposition 3.1.2.1. With nonnegative initial conditions all solutions of model (3.1)
are nonnegative.
The unique steady state (E = (0, 0)) implies population extinction. A solution of
(3.1) either approaches E or the population size grows unbounded under endemic or
infection-free conditions, depending on different parameter values:
• When r < µ, (S(t), I(t))→ (0, 0).
• When r > µ, and further β > d and µ+ d > r,
– when β < µ+ d, (S(t), I(t))→ (∞, 0) unbounded infection free;
– when µ+ d < β < (µ+d)d
µ+d−r , (S(t), I(t))→ (∞,∞) unbounded endemic;
– when β > (µ+d)d
µ+d−r , (S(t), I(t))→ (0, 0) extinction.
See Appendix C for proof. Notice that boundedness of solutions is not observed.
HIV prevalence is estimated and reported periodically in the statistical data.
Therefore to study the projected HIV prevalence by the model, the dynamics of
the fractional form of model (3.1) in terms of s = S
N
and i = I
N
= 1 − s are also
analyzed:
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ds
dt
= [r − (β − d)s](1− s)
dN
dt
= [r − µ− d(1− s)]N
dI
dt
= [βs− (µ+ d)]I.
Notice that the first equation is independent of N which allows to study s(t)
directly. The following proposition summarizes the solution behavior for different
parameter values and initial conditions.
Proposition 3.1.2.2. With no infected individuals initially (i(0) = 0 ,s(0) = 1), the
population remains disease free (s(t) ≡ 1) with population size given by dN
dt
= (r−µ)N .
Any other initial conditions result in one of the following cases (assume r > µ,
β > d, and µ+ d > r):
• when β < µ+ d, (S(t), I(t))→ (∞, 0) with (s(t), i(t), N(t))→ (1, 0,∞);
• when µ+d < β < r+d, (S(t), I(t))→ (∞,∞) with (s(t), i(t), N(t))→ (1, 0,∞);
• when r + d < β < (µ+d)d
µ+d−r , (S(t), I(t)) → (∞,∞) with (s(t), i(t), N(t)) →
( r
β−d , 1− rβ−d ,∞);
• when β > (µ+d)d
µ+d−r , (S(t), I(t))→ (0, 0) with (s(t), i(t), N(t))→ ( rβ−d , 1− rβ−d , 0).
See Appendix C for proof.
3.1.3 Models with Logistic Recruitment
In this section, it is assumed that f(N) = rN(1− N
K
) in model (3.1).
Notice that
lim
(S,I)→(0,0)
SI
N
= lim
(S,I)→(0,0)
SI
S + I
= 0.
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It is defined that P (0, 0) = 0 and Q(0, 0) = 0. Under this assumption, E00 = (0, 0)
is a steady state of (3.1) and the right-hand sides (P (S, I) and Q(S, I)) of (3.1) are
continuous in {(S, I)|S ≥ 0, I ≥ 0}.
Proposition 3.1.3.1. The biologically relevant region {(S(t), I(t))|S(t) ≥ 0, I(t) ≥
0, S(t) + I(t) ≤ K} is positively invariant with respect to (3.1).
The model has three possible steady states: population extinction E00 = (0, 0),
disease-free E01 = (
r−µ
r
K, 0) and endemic E∗ =
r−µ−d(1− 1
R0
)
r
K( 1
R0
, R0−1
R0
) where R0 =
β
µ+d
.
The following global stability results hold.
• When r < µ, (S(t), I(t))→ E00 the extinction steady state.
• When r > µ, and further β > d and µ+ d > r,
– when β < µ + d, (S(t), I(t)) → E01 the infection free steady state, while
E00 is unstable and E
∗ does not exist;
– when µ+d < β < (µ+d)d
µ+d−r , (S(t), I(t))→ E∗ the endemic steady state, while
E00 and E01 are unstable;
– when β > (µ+d)d
µ+d−r , (S(t), I(t)) → E00 the extinction steady state, while E01
and E∗ are unstable.
See Appendix C for proof.
The behavior of the model (3.1) can be further studied by investigating its frac-
tional form in terms of s = S
N
and i = I
N
= 1− s:
ds
dt
= [r(1− N
K
) + (d− β)s](1− s)
dN
dt
= [r(1− N
K
)− µ− d(1− s)]N.
(3.2)
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Proposition 3.1.3.2. Model (3.2) is used to study the local stability of the extinction
steady state E00. The following results hold:
• E00 is unstable when β < (µ+d)dµ+d−r ;
• E00 is stable when β > (µ+d)dµ+d−r .
See Appendix C for proof.
Table 3.2 summarizes the long-term dynamic results when the model (3.1) is using
different recruitment rates. Notice that β = β˜ , (µ+d)d
µ+d−r makesE4 = (
1
R0
,
r−µ−d(1− 1
R0
)
r
K)
= E2 = (
r
β−d , 0) for (3.2).
Table 3.2: Stability conditions for the models in absence of PrEP. Extinction steady
state is globally stable when r < µ, so in the table it is assumed that r > µ and
further assumed that β > d and µ+ d > r for linear and logistic entrance rates.
Recruitment type Parameter conditions Outcomes HIV prevalence
Constant β < µ+ d disease free state 0
β > µ+ d endemic state 1− µ+d
β
Linear β < µ+ d disease free state 0
µ+ d < β < (µ+d)d
µ+d−r endemic state 0 or 1− rβ−d
β > (µ+d)d
µ+d−r extinction 1− rβ−d
Logistic β < µ+ d disease free state 0
µ+ d < β < (µ+d)d
µ+d−r endemic state 1− µ+dβ
β > (µ+d)d
µ+d−r extinction 1− rβ−d
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3.2 Models with PrEP Intervention
Next, it will be investigated the influence of the recruitment mechanisms on the
projected impact of PrEP interventions. The model with intervention is formulated
by the following system of differential equations:
dSp
dt
= kf(N)− (1− αs)β SpIN − µSp
dS
dt
= (1− k)f(N)− β SI
N
− µS
dI
dt
= β SI
N
+ (1− αs)β SpIN − (µ+ d)I
(3.3)
with initial conditions:
Sp(0) = k(1− P )N(0)
S(0) = (1− k)(1− P )N(0)
I(0) = PN(0).
Here P is the initial HIV prevalence, N(0) is the initial population size, and k
is the initial coverage of PrEP among susceptible individuals. All parameters are
explained in Table 3.1.
In this model the population is divided into three major classes, according to
their HIV and PrEP status: susceptible individuals who don’t use PrEP (S); sus-
ceptible PrEP users (Sp) and infected individuals (I). A constant proportion k
of the new recruits are assumed to start using PrEP. The same proportion of the
susceptible individual are assumed to start on PrEP initially. Since PrEP pro-
vides imperfect protection against HIV some of the PrEP users become infected.
The risk of drug-resistance emergence among infected PrEP users has been dis-
cussed in the HIV prevention community (Dimitrov et al. (2012); Supervie et al.
(2011, 2010)) and wide-scale PrEP interventions will likely include periodic HIV
screening of all prescribed users. Therefore, it is assumed that PrEP users stop
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using the product after acquiring HIV and all infected individual accumulate in
the compartment (I). The basic reproduction number of model (3.3) is given by
R0 = (1− k)R0(S) + kR0(Sp) , (1− k) βµ+d + k (1−αs)βµ+d = (1−αsk)βµ+d .
Different expressions (f(N) = Λ, f(N) = rN , and f(N) = rN(1 − N
K
)) will be
explored for the population recruitment.
3.2.1 Intervention Models with Constant Recruitment
In this section, it is assumed that f(N) = Λ in model (3.3).
Proposition 3.2.1.1. With nonnegative initial conditions, solutions for (3.3) are
nonnegative and bounded with N(t) = max{N(0), Λ
µ
}. Now assume β > d.
• When R0 < 1 the model (3.3) has an unique (disease-free) equilibrium E0 =
( k
µ
Λ, 1−k
µ
Λ, 0) which is stable. Global stability of E0 has been proved given extra
condition R0 <
µ
µ+d
.
• When R0 > 1 the disease-free equilibrium E0 is unstable. The system has a
single endemic equilibrium E∗ = (Sp∗, S∗, I∗) which satisfies Sp∗ =
Λ(Λ− dI∗)
µ
·
k
Λ + ((1− αs)β − d)I∗ and S
∗ =
Λ(Λ− dI∗)
µ
· 1− k
Λ + (β − d)I∗ , where I
∗ is the
unique solution of F (I) , Λ− kΛ(Λ− dI)
(1− αs)βI + Λ− dI −
(1− k)Λ(Λ− dI)
βI + Λ− dI − (µ+
d)I = 0 in the interval (0, Λ
d
). The endemic equilibrium E∗ is stable when
µ+d
d
[(1− αs)β − d] + αs(1− k)d > 0. (E∗ may be stable whenever exists, can be
further studied in future.)
Hyman and Li (2000, 2005a,b, 2006) have studied epidemic models with differ-
ential infectivity and differential susceptibility in several papers. In particular, they
studied a general compartmental differential susceptibility SIR model with disease-
induced mortality in Hyman and Li (2005a). So here to get some results on the
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positive steady state(s), the same technique is applied as in section 3.2 of Hyman and
Li (2005a) to the model with intervention and constant entrance rate. See proof for
Proposition 3.2.1.1 in Appendix C.
3.2.2 Intervention Models with Linear Recruitment
In this section, it is assumed that f(N) = rN in model (3.3).
Notice that
lim
(Sp,S,I)→(0,0,0)
SpI
N
= lim
(Sp,S,I)→(0,0,0)
SpI
Sp + S + I
= 0
and
lim
(Sp,S,I)→(0,0,0)
SI
N
= lim
(Sp,S,I)→(0,0,0)
SI
Sp + S + I
= 0.
It is defined that P (0, 0, 0) = Q(0, 0, 0) = R(0, 0, 0) = 0. Under this assumption, E =
(0, 0, 0) is a unique steady state of (3.3), and P (Sp, S, I), Q(Sp, S, I) and R(Sp, S, I)
are continuous in {(Sp, S, I)|Sp ≥ 0, S ≥ 0, I ≥ 0}.
Proposition 3.2.2.1. All solutions of (3.3) with nonnegative initial conditions re-
main nonnegative.
Periodic solutions for (3.3) do not exist when β − d > 0.
The unique steady state (E = (0, 0, 0)) implies population extinction. It is globally
stable if r < µ.
Assume r > µ and β > d,
• when (1−k)β+k(1−αs)β < d+r, E1 = (k, 0) is globally stable (see Proposition
3.2.2.2), with lim
t→∞
N(t) =∞ and
– lim
t→∞
I(t) = 0 if R0 < 1,
– lim
t→∞
I(t) =∞ if R0 > 1;
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• when (1−k)β+k(1−αs)β > d+r, E2 = (p∗, i∗) is globally stable (see Proposition
3.2.2.2),
– lim
t→∞
N(t) = 0 if i∗ > r−µ
d
, and lim
t→∞
I(t) = 0,
– lim
t→∞
N(t) =∞ if i∗ < r−µ
d
, and lim
t→∞
I(t) =∞.
See proof in Appendix C.
Similar to the scenarios without intervention, the dynamics of the fractional form
of (3.1) will be studied in terms of p = S
p
N
, s = S
N
, then i = I
N
= 1− p− s:
dp
dt
= kr − rp− [(1− αs)β − d]pi , X(p, i) (3.4)
di
dt
= [β − (d+ r)− αsβp− (β − d)i]i , Y (p, i) (3.5)
dN
dt
= [r − µ− di]N (3.6)
dI
dt
= [β(1− p− i) + (1− αs)βp− (µ+ d)]I. (3.7)
which allows to understand the expected changes in HIV prevalence due to PrEP use.
Notice that the first two equations are decoupled from the rest of the system which
allows to study the reduced system (3.4) and (3.5).
Proposition 3.2.2.2. The biologically relevant region {(p(t), i(t))|p(t) ≥ 0, i(t) ≥
0, p(t) + i(t) ≤ 1} is positively invariant with respect to (3.4) and (3.5).
When β − d > 0, periodic solutions do not exist for the transformed system.
E1 = (k, 0) for the reduced system is stable when (1−k)β+k(1−αs)β < d+r, and
is globally stable if further assume β > d. A positive steady state E2 = (p
∗, i∗) of the
reduced system exists and is globally stable provided that (1−k)β+k(1−αs)β > d+r.
See proof in Appendix C.
A summary on the global stability results confirmed by simulations is provided in
Table 3.3.
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3.2.3 Intervention Models with Logistic Recruitment
In this section, it is assumed that f(N) = rN(1− N
K
) in model (3.3).
Notice that
lim
(Sp,S,I)→(0,0,0)
SpI
N
= lim
(Sp,S,I)→(0,0,0)
SpI
Sp + S + I
= 0
and
lim
(Sp,S,I)→(0,0,0)
SI
N
= lim
(Sp,S,I)→(0,0,0)
SI
Sp + S + I
= 0.
It is defined that P (0, 0, 0) = Q(0, 0, 0) = R(0, 0, 0) = 0. Under this assumption,
E00 = (0, 0, 0) is a steady state of (3.3), and P (S
p, S, I), Q(Sp, S, I) and R(Sp, S, I)
are continuous in {(Sp, S, I)|Sp ≥ 0, S ≥ 0, I ≥ 0}.
Proposition 3.2.3.1. The biologically relevant region {(Sp(t), S(t), I(t))|Sp(t) ≥
0, S(t) ≥ 0, I(t) ≥ 0, Sp(t) + S(t) + I(t) ≤ K} is positively invariant with respect
to (3.3).
The model has three possible steady states: population extinction E00 = (0, 0, 0),
disease-free E01 = (k
r−µ
r
K, (1− k) r−µ
r
K, 0) and endemic E∗ = (Sp∗, S∗, I∗) .
The extinction steady state is globally stable if r < µ.
Assume r > µ,
• the infection free steady state E01 is stable when R0 < 1 and unstable when
R0 > 1;
• the extinction steady state E00 is stable when (1− k)β+ k(1−αs)β > d+ r and
unstable when (1− k)β + k(1− αs)β < d+ r;
• further assume β > µ+ d, then the positive steady state E∗ exists when R0 > 1
and i∗ = I
∗
N∗ <
r−µ
d
and does not exist when R0 < 1 or i
∗ = I
∗
N∗ >
r−µ
d
.
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See proof in Appendix C.
The behavior of the model (3.3) is further studied by investigating its fractional
form in terms of p = S
p
N
, s = S
N
, and i = I
N
= 1− p− s:
dp
dt
= kr(1− N
K
)− r(1− N
K
)p− [(1− αs)β − d]pi
di
dt
= [β − d− r(1− N
K
)− αsβp− (β − d)i]i
dN
dt
= [r(1− N
K
)− µ− di]N
(3.8)
Proposition 3.2.3.2. Assume r > µ.
Equilibrium E1 = (k, 0, 0) for (3.8) is unstable.
Equilibrium E2 = (p
∗, i∗, 0) (p∗ > 0, i∗ > 0) for (3.8) does not exist when (1 −
k)β + k(1− αs)β < d+ r and is stable otherwise.
Equilibrium E3 = (k, 0,
r−µ
K
) (infection free steady state) for (3.8) is stable when
R0 < 1 and unstable otherwise.
Further assume β > µ+ d, then a positive steady state E4 = (p
∗, i∗, N∗) for (3.8)
exits when R0 > 1 and i
∗ < r−µ
d
and does not exist otherwise.
See proof in Appendix C.
A summary of the asymptotic behavior of the system with PrEP confirmed by
simulations is provided in Table 3.3.
Next, a threshold value β˜ (used in Table 3.3) will be determined for β. β˜ will be
derived from substituting (p∗log, i
∗
log =
r−µ
d
, 0) into (3.8). First
r − µ
d
= i∗ =
β˜ − µ− d− αsβ˜p∗
β˜
leads to p∗ = (1−i
∗)β˜−µ−d
αsβ˜
. Then from (3.8),
dp∗
dt
= 0
implies
kr(1− N
∗
K
)− r(1− N
∗
K
)p∗ − [(1− αs)β˜ − d]p∗i∗ = 0
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Table 3.3: Models with intervention, assume r > µ and β > d. Notice that β˜ is a
solution to (3.9). i∗lin is the i
∗ appears in Proposition 3.2.2.1 and 3.2.2.2. i∗log is the i
∗
appears in Proposition 3.2.3.1 and 3.2.3.2.
Recruitment type Parameter conditions Outcomes HIV prevalence
Constant β < µ+d1−αsk disease free state 0
β > µ+d1−αsk endemic state
µI∗
Λ−dI∗
Linear β < µ+d1−αsk disease free state 0
µ+d
1−αsk < β < max{ r+d1−αsk , β˜} endemic state 0 or i∗lin(<
r−µ
d )
β > β˜ extinction i∗lin(>
r−µ
d )
Logistic β < µ+d1−αsk disease free state 0
µ+d
1−αsk < β < max{ r+d1−αsk , β˜} endemic state i∗log(<
r−µ
d )
β > β˜ extinction i∗log(>
r−µ
d )
, i.e.,
kr − rp∗ − [(1− αs)β˜ − d]p∗i∗ = 0
with p∗ = (1−i
∗)β˜−µ−d
αsβ˜
and i∗ = r−µ
d
. This eventually can be simplified to be
krαsβ˜ − [(1− i∗)β˜ − µ− d][i∗(1− αs)β˜ + µ] = 0
where i∗ = r−µ
d
or
krαsβ˜ − [(1− r − µ
d
)β˜ − µ− d][r − µ
d
(1− αs)β˜ + µ] = 0. (3.9)
Some bifurcation results are presented in Figure 3.1. Note that the trajectories
of the models with constant and logistic recruitment are bounded while the linear
recruitment allows for unbounded solutions. As the HIV risk (β) increases, the model
with constant recruitment switches from infection-free to endemic steady state while
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the model with logistic recruitment equilibrium goes from infection-free to endemic
equilibrium and further to population extinction. The trajectories of the linear model
follow a similar pattern as the logistic recruitment model: from unbounded infection-
free through unbounded endemic state to population extinction. However, the transi-
tion (bifurcation) points where the behavior changes occur are different for the three
models. As a result the projected long-term prevalence with each of the three models
differ for epidemic conditions with R0 greater than one.
What in common for all the three models is when R0 < 1, the status of the
population approaches infection free; when R0 > 1, the status of the population
approaches coexistence or extinction.
These figures in Figure 3.2 illustrate the possible solutions that can not be ex-
pressed explicitly in the previous analysis work. Figure 3.2 and 3.1 both confirm the
propositions that haven been proved and the summary proposed in Table 3.3.
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Figure 3.1: Bifurcation diagrams of models employing different recruitment functions:
(a-b) constant; (c-d) linear; (e-f) logistic. Epidemic parameter values (except β) are
chosen by fitting projected HIV populations to data from South Africa (see Table
D.1). PrEP coverage (k = 0.2) and PrEP efficacy (αs = 0.5) are assumed. Initial
conditions are adapted from year 2011.
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(a) (b)
(c) (d)
Figure 3.2: Parameter values(except β, see Table D.1) are chosen from data fitting,
with k = 0.2 and αs = 0.5 are assumed. Initial conditions are adapted from year
2011. Figures are truncated for better view. Figure (a) corresponds to model (3.3)
with constant entrance. Figure (b) corresponds to the transformed system (3.4) with
linear entrance. Figures (c) and (d) both correspond to transformed system (3.8)
with logistic entrance. (c) highlights possible steady states (p∗ > 0, i∗ > 0, N∗ = 0),
and (d) highlights possible steady state (p∗ > 0, i∗ > 0, N∗ > 0).
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3.3 Public-health Impact of PrEP Use
3.3.1 Parameterizations and Simulations
The models are simulated using different recruitment mechanisms (different f(N)),
and keeping all the remaining parameters the same. It is assumed that the annual
influx of people in the population is 1,000,000 initially, and then the parameter val-
ues are calculated corresponding to such recruitment for each mechanism. Therefore,
Λ = 106 is used for the model with constant recruitment, r = 10
6
N0
for the model with
linear recruitment and r = 10
6K
N0(K−N0) with K = 9 × 107 (Figure A.1) for the model
with logistic recruitment, where N0 = 27172431 is the initial population size from
Table A.1.
The resulting population dynamics over 70 years under scenarios with and with-
out PrEP are presented in Figure 3.3. Note that with identical initial recruitment
and using the same values for all other parameters the population dynamics substan-
tially diverge over the simulated period. In absence of PrEP, the population suffers
the smallest decrease in size (34%) under the constant recruitment scenario because
the disease-related mortality does not impact the influx of newly susceptible people
(Figure 3.3 (a),(b),(c)). In comparison, the population loses 67% and almost 83%
over 70 years under the logistic and linear recruitment scenarios. In addition to the
population size the proportion of infected individuals is affected as well. Starting
at 16.6% the models predict that the HIV prevalence will raise to 25.4% with con-
stant, 32.9% with logistic and 41.9% with linear recruitment (Figure 3.3 (d)). The
results do not change qualitatively if 20% of the population use PrEP. Naturally,
for all recruitment methods the projected number of susceptibles is larger compared
to the scenario without PrEP. However, the model with constant recruitment also
projects smaller number of infected vs the scenario without PrEP while the model
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with linear recruitment shows substantial increase in infected individuals due to the
fact that healthier population size is preserved when PrEP is used. The relative order
of projected population size by recruitment mechanism remains the same (Figure 3.3
(e),(f),(g)). The model with linear recruitment is most pessimistic with respect to
HIV prevalence ( 18.8%) while the other two mechanisms predict decrease of HIV
prevalence to 15.9% and 14.4%.
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Figure 3.3: Population dynamics for models with different recruitment rates: constant
(blue), linear (red), and logistic (black). Initial recruitment and parameter values
unrelated to recruitment are kept the same across the models (see Table D.1).
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3.3.2 Influence of Recruitment on the PrEP Effectiveness
The effectiveness of PrEP use is often evaluated by different quantitative indica-
tors. It has been demonstrated in previous work that the choice of evaluation method
may influence the conclusions of the modeling analyses (Zhao et al. (2013)). Here,
study will focus on four indicators already used in modeling studies to quantify the
impact of PrEP interventions (see Table 3.4). The fractional indicator (FI) measures
the intervention effectiveness based on the difference in expected infections between
scenarios with and without PrEP. The prevalence (PI) and incidence (aII) indicators
measure the reduction in the projected HIV prevalence and incidence due to PrEP,
respectively. The last evaluation method (FˆI) is based on the reduction of the number
of infected individuals and correlates with the economic burden of the HIV epidemic
on the public health system at community and state level since the money allocated
for HIV treatment is proportional to the size of the infected population.
Table 3.4: Indicator description
Indicator Name Description
FI(T ) Fractional indicator Fraction of infections prevented
over the period [0, T ] due to the usage of PrEP
PI(T ) Prevalence indicator Reduction in HIV-prevalence
at time t = T due to the usage of PrEP
aII(T ) Incidence indicator Reduction in the annual HIV incidence
at time t = T due to the usage of PrEP
FˆI(T ) Fractional reduction Fraction of the projected number of infected
indicator at time t = T reduced due to the usage of PrEP
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To track the cumulative number of new infections over time, the following equation
is added to model (3.1):
d(INew)
dt
= β
SI
N
,
and similarly to model (3.3):
d(INew)
dt
= β
SI
N
+ (1− αs)βS
pI
N
.
[ ] is used to denote variables from the model without PrEP (3.1) and [ ]P for
variables from the model with PrEP (3.3). Using these notations, the qualitative
indicators are defined as follows:
FI(T ) =
[INew(T )]−[IpNew(T )+INew(T )]P
[INew(T )]
= 1− [I
p
New(T )+INew(T )]P
[INew(T )]
PI(T ) = 1− [
Ip(T )+I(T )
Sp(T )+S(T )+Ip(T )+I(T )
]P
[
I(T )
S(T )+I(T )
]
aII(T ) = 1− [
I
p
New
(T+1)+INew(T+1)−(I
p
New
(T )+INew(T ))
Sp(T )+S(T )
]P
[
INew(T+1)−INew(T )
S(T )
]
FˆI(T ) =
[I(T )]−[Ip(T )+I(T )]P
[I(T )]
= 1− [Ip(T )+I(T )]P
[I(T )]
.
The impact of the recruitment on the projected PrEP effectiveness is investigated
in Figure 3.4. The choice of recruitment mechanisms shows no substantial impact over
the initial period of 20-30 years but leads up to 21% difference in predicted reduction
in HIV prevalence and incidence after 70 years (Figure 3.4 (a),(b)). The model using
linear recruitment is most optimistic predicting 55% reduction in HIV prevalence and
61% in HIV incidence, respectively. Conversely, the model with constant recruitment
projects largest fraction of infection prevented (Figure 3.4 (c)). Interestingly, the
same indicator projects negative overall PrEP impact of the models with linear and
logistic recruitment in a long term. It is a result of the critical decline in population
size under the scenario without PrEP which limits the number of HIV infections in a
long term.
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Effectiveness indicators (k=0.2, α
s
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Figure 3.4: Dynamics of PrEP effectiveness for models with different recruitment
rates: constant (blue), linear (red), and logistic (black). Initial recruitment and
parameter values unrelated to recruitment are kept the same across the models (see
Table D.1). Some indicators take negative values for models with linear entrance rate
and logistic entrance rate (not shown).
Finally, simulation of the HIV epidemics has been done by fitting the models with
different recruitment to 10-year HIV data representative for South Africa. Parameters
values (see Table D.1) were determined to minimize the L1 norm of the difference be-
tween projected HIV population and data in absence of PrEP following the approach
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proposed in a previous study (Zhao et al. (2013)). The relative short duration of
the fitted period did not allow for significant difference in the “best fit” parameters
across models. As a result the predictions of HIV dynamics and PrEP effectiveness
with that “best fit” parameter sets (see Figure D.1 and Figure D.2 in the Appendix),
were qualitatively similar to the simulations with fixed parameter sets (Figure 3.3
and 3.4).
3.4 Discussion
Mathematical models are employed to estimate the expected effectiveness of differ-
ent interventions for HIV prevention under various epidemic settings. In this paper it
has been demonstrated that the assumptions regarding population recruitment have
a strong influence on the future course of the HIV epidemic and as a result impacts
the projected success of the planned interventions. Models are compared equipped
with three distinct recruitment mechanisms (constant, linear and logistic) and studied
their behavior. The analysis shows that the three models posses qualitatively different
dynamic characteristics. The model with constant recruitment always stabilizes in
population size and supports two asymptotic states, corresponding to disease-free and
endemic equilibrium respectively. In comparison, linear and logistic recruitment sup-
port three asymptotic states including disease free equilibrium, endemic equilibrium
and population extinction under the pressure of HIV. The parameter conditions (bi-
furcation points) where the transitions between asymptotic states occur are the same
for these two models but different from those for the model with constant recruit-
ment. On the other hand, constant and logistic model share an endemic fractional
equilibrium which is different from the linear model, i.e., they project different HIV
prevalence over long-term.
As a result the simulations of the HIV epidemics with the three models over 70
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years show large discrepancies in population size and epidemic distribution under
identical initial conditions and forces of infection. The projected HIV prevalence
varies from 25% when constant recruitment is assumed and 42% when linear recruit-
ment is assumed. In addition, significant difference in the reduction in HIV prevalence
and incidence (almost 20%) is predicted when 50% effective PrEP is used by 20% of
the population. Over the entire simulated period, linear recruitment provides the
most optimistic estimates of the PrEP effectiveness in terms of prevalence reduction
while constant recruitment predicts larger fraction of infections prevented.
It can be argued that regardless of the differences in the dynamic behavior all
three models agree in their effectiveness projections over 20-30 years which is the usual
period over which the intervention are evaluated. However, often the models are run
for extended periods in order to simulate “mature” epidemics and the intervention is
introduced afterwards. The key message of this analysis is that the way recruitment is
incorporated in the models impacts the HIV epidemic and may have significant effect
on the projected effectiveness of different HIV intervention in a short and long term.
Demographic data, including statistics on births and age-specific mortality, should be
used to inform the modeling mechanisms before HIV prevention is considered.
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Chapter 4
BAYESIAN PARAMETER ESTIMATION
Previously, I tried to fit models to the data by minimizing the L1 norm of the difference
between projected HIV population and data (Figure D.1). This approach starts with
a single set of initial guess values for the parameters, and ends up with another single
set of approximated parameter values that make the model fit the data best. It
works by finding the set of parameter values that minimize the sum of the absolute
differences between the data and the model predictions. The issue is that this method
only provides point estimates and does not tell how strongly the data supports these
particular estimates. Distributions provide much more information than the point
estimates. In reality, information on distributions of certain parameters can often be
found in literature (see Table 4.1).
The Bayesian estimation of an unknown parameter Θ using some newly acquired
data can be worked out based on Bayes’ formula. First what is needed is the likelihood
function p(D|Θ = θ), which specifies the conditional distribution of the data (D) on
each possible set of parameter values (Θ = θ). Then I choose some prior distribution
p(θ) which indicates how strongly Θ = θ is believed before accessing the new data.
Finally using the information provided by the new data, Bayes’ formula p(θ|D) =
p(θ)
p(D|θ)
p(D)
provides the posterior distribution given the new data. The belief in how
strong Θ = θ now has been modified from p(θ) to p(θ|D).
Therefore, in this chapter, a second approach I will try is the Bayesian parameter
estimation on fitting ODE model to the related HIV data. Now one can start with
a set of prior distributions for the parameters as initial guess, and try to obtain a
set of posterior distributions for the parameters which make the model fit the data
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best. Prior distributions are distributions of the parameters assigned before data
is observed. Prior distributions can either be derived from existing literature or
be assumed. Posterior distributions are obtained by Bayesian inference given the
observed data.
ODEs are not based on a probability model, to apply Bayesian inference directly
on ODEs, likelihoods are therefore generally defined in a nonlinear regression context,
such as assuming that the data are normally distributed around the deterministic
solution(Toni et al. (2009); Vyshemirsky and Girolami (2008)).
In this chapter, I will try Bayesian method on estimating the parameters for model
(4.1) from data on South Africa HIV population of year 2001-2011 (Table A.1).
4.1 Model
dS
dt
= Λ− β SI
N
− µS
dI
dt
= β SI
N
− (µ+ d)I
(4.1)
Model (4.1) is the HIV model without intervention. See Table 4.1 for more infor-
mation on the parameters. Throughout this chapter, Λ derived from Table A.1 will be
assumed to be constant entrance rate. β, calculated from ba and n (β = 1−(1−ba)n),
will be studied directly. I will start with prior distributions on µ, d, and β, then apply
Bayesian method to get posterior distributions for these parameters.
4.2 Parameter Prior Distributions
Table 4.1 has showed information on mean and possible confidence intervals from
literature for parameters ba, n, µ, and d. Then I assume lognormal distributions for ba,
µ, d, and Poisson distribution (Boily et al. (2009)) for n. The lognormal distributions
were chosen for ba, µ, and d since these parameters must be non-negative. To fit
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Table 4.1: Parameter description and values from literature
Par. Description Mean 95% CI Reference
Λ Annual rate 996344 derived from Table A.1
at which individuals
become sexually active
ba HIV acquisition risk per act 0.0038 0.0013-0.011 Boily et al. (2009)
n Number of sexual acts 120 Wawer et al. (2005),
per year per individual Boily et al. (2009)
β Cumulative derived from ba and n
HIV-acquisition risk
1
µ Time (in years) 35 UNAIDS (2009)
to remain sexually active
d HIV carrier’s annual rate 1/10.9 1/11.3-1/10.6 Porter and Zaba (2004)
of progression to AIDS
the confidence intervals best (see (b) and (c) in Figure 4.1), I found the log standard
deviations for ba and d as in Table 4.2. For µ, log standard deviation is assumed to
be 0.15.
Recall that when I minimized the L1 norm of the difference between HIV popu-
lations from ODE model and from data (Figure D.1), I obtained µ = 0.029793556,
d = 0.119146121, and β = 0.196924711. Notice that the value for d is not consistent
with the prior distribution as in Figure 4.1(b). This reminds me to revisit the liter-
ature from which I obtained the prior distribution for d. 10.9 years was observed in
industrialized countries, as mean survival time for those aged 24-35 years at serocon-
version, with 95% CI 10.6-11.3 years (Babiker et al. (2000); Porter and Zaba (2004)).
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Here, I expect the mean time to be shorter to develop AIDS in South Africa compared
with industrialized countries. Also notice that age group 15-49 years is studied instead
of 24-35 years, so a wider 95% confidence interval should be expected. Therefore I
will increase the corresponding standard deviation.
To make a better prior for d, I modify the prior distribution for d by increasing
σ2 from 0.0161875 to 0.25. Then the prior distribution for d is modified as in Figure
4.1(f).
Table 4.2: Assumptions for parameters. dˆ is modified d. β = 1− (1− ba)n.
Par. Distribution Log mean Log standard Mean Standard 95% CI
deviation deviation
Λ constant
ba lognormal ln(0.0038) 0.542394 0.004402 0.0025746 0.0013126
-0.011001
n Poisson 120
β β = β(ba, n)
µ lognormal ln(1/35) 0.15(assumed) 0.028895 0.0043587
d lognormal ln(1/10.9) 0.0161875 0.091755 0.0014854 0.088888
-0.09469
dˆ lognormal ln(1/10.9) 0.25 0.094655 0.024038
Now the probability density functions (PDF) for the prior distributions have been
derived as following.
µ has lognormal PDF p(µ) =
1
µσ1
√
2pi
e
− (ln(µ)−µ1)2
2σ21 with µ1 = ln(1/35) and σ1 =
0.15.
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d has the lognormal PDF p(d) =
1
dσ2
√
2pi
e
− (ln(d)−µ2)2
2σ22 with µ2 = ln(1/10.9) and
σ2 = 0.25.
ba has the lognormal PDF p(ba) =
1
baσ4
√
2pi
e
− (ln(ba)−µ4)2
2σ24 with µ4 = ln(0.0038) and
σ4 = 0.542394.
n has the Poisson PDF p(n) =
λn
n!
e−n with λ = 120. For convenience, the
Poisson distribution for n is approximated by a normal distribution with mean 120
and standard deviation
√
120. So it is approximated by the normal PDF p(n) =
1√
2piσ5
e
− (n−µ5)2
2σ25 , with µ5 = 120 and σ5 =
√
120 (see Figure 4.1(d)).
Since ba and n are independent, then the cumulative distributive function (CDF)
for β becomes
F (β) =
∫ 1
0
∫ ln1−ba (1−β)
0
p(ba)p(n) dndba,
and the PDF for β is
p(β) =
d
dβ
F (β) =
d
dβ
[∫ 1
0
∫ ln1−ba (1−β)
0
p(ba)p(n) dndba
]
.
Then by Leibniz rule,
p(β) =
∫ 1
0
p(ba)p(n(ba, β))
−1
(1− β) ln(1− ba) dba
=
∫ 1
0
1
baσ4
√
2pi
e
− (ln(ba)−µ4)2
2σ4
2
1√
2piσ5
e
− (log1−ba (1−β)−µ5)
2
2σ5
2
−1
(1− β) ln(1− ba) dba,
(4.2)
with µ4 = ln(0.0038), σ4 = 0.542394, µ5 = 120, and σ5 =
√
120.
This can be approximated by a lognormal distribution of PDF p(β) ≈ 1
βσ3
√
2pi
·
e
− (ln(β)−µ3)2
2σ23 with µ3 = ln(0.3704) and σ3 = 0.4422 (see Figure 4.1(e)).
Then the prior distributions for µ, d, and β are illustrated in Figure 4.1 and
summarized in Table 4.3.
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Figure 4.1: Parameter prior distributions. 95% confidence intervals(dashed black) are
also included for ba and d. Poisson distribution and approximated normal distribution
have both been included for n. Calculated distribution (4.2) and approximated log-
normal distribution have both been included for β. Solid black lines indicate values
obtained from data fitting as in Figure D.1. (f) is a modification of (b) with a larger
standard deviation.
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Table 4.3: Parameter prior distributions
Par. Distribution Log mean Log standard Mean Standard
deviation deviation
µ lognormal µ1 = ln(1/35) σ1 = 0.15 0.028895 0.0043587
d lognormal µ2 = ln(1/10.9) σ2 = 0.25 0.094655 0.024038
β lognormal µ3 = ln(0.3704) σ3 = 0.4422 0.40844 0.18981
Let zi represent the i
th year HIV infected population since 2001 from data (z0:T ),
and xi represent the i
th year HIV infected population predicted by the model (x0:T ).
Because of the observation error (assumed to be normally distributed with stan-
dard deviation σ) in z0:T , another two parameters are added into the study: the
starting point of HIV population in the model x0, and the related standard deviation
σ. x0 and σ are not independent since x0 depends on both z0 and σ.
Notice that only positive values are acceptable for x0, so let p(x0|z0, σ) = 0 is
assumed when x0 ≤ 0 and
p(x0|z0, σ) = 1√
2piσ2
e−
(x0−z0)2
2σ2 /
∫ ∞
0
1√
2piσ2
e−
(x−z0)2
2σ2 dx = e−
(x0−z0)2
2σ2 /
∫ ∞
0
e−
(x−z0)2
2σ2 dx
(4.3)
when x0 > 0.
I did not find a prior distribution for σ from literature, therefore I choose a non-
informative prior distribution which is invariant under reparameterization. Since the
likelihood is normal with known mean and unknown standard deviation σ (see (4.4)),
then I assume a Jeffreys prior for σ as
p(σ) ∝ 1
σ
with σ ∈ [1, 106]
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or p(σ) = Cσ
σ
with σ ∈ [1, 106] and Cσ = 16 ln(10) . Since the observed HIV population
as in Table A.1 shows x0 ∈ [3.8 × 106, 4.6 × 106], it is practical to assume that the
possibility of σ lies outside [1, 106] is negligible, with σ being the standard deviation
when the observation is normally distributed.
Then prior for x0 becomes
p(x0|z0) =
∫ 106
1
p(σ)p(x0|z0, σ) dσ =
∫ 106
1
p(σ)
1∫∞
0
e−
(x−z0)2
2σ2 dx
e−
(x0−z0)2
2σ2 dσ,
with p(σ) = Cσ
σ
.
Then
p(x0) ≈
∫ 106
1
Cσ
σ
1√
2piσ
e−
(x0−z0)2
2σ2 dσ =
∫ 106
1
Cσ√
2piσ2
e−
(x0−z0)2
2σ2 dσ
v=
x0−z0√
2σ
=======
Cσ√
pi(x0 − z0)
∫ x0−z0√
2
x0−z0√
2
10−6
e−v
2
dv(when x0 6= z0),
and
p(x0 = z0)
u= 1
σ====
∫ 1
10−6
Cσ√
2pi
du =
Cσ(1− 10−6)√
2pi
.
Thus, all the prior distributions needed for Bayesian inference have been derived
(see Figure 4.1 and 4.2).
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Figure 4.2: Figure (a) is the prior distribution for x0 when σ = 6.4 × 104 is fixed.
Figure (c) is the prior distribution for x0 when σ has a Jeffreys prior as in figure (b).
4.3 Bayesian Estimation
Now that parameter prior distributions have been derived, Bayesian method is
ready to be applied.
Let θ = (θ1, θ2, θ3, σ, x0) = (µ, d, β, σ, x0) represent 5 parameters to be studied and
denote D = z0:T .
Bayesian inference computes the posterior distributions according to the Bayes’
63
formula
p(θ|D) = p(θ)p(D|θ)
p(D)
,
where
• p(θ) represents the prior density, the probability of θ before D is observed;
• p(θ|D) represents the posterior probability, the probability of θ after D is ob-
served;
• p(D|θ) is the likelihood (or sampling probability for D), the probability of ob-
serving D given θ;
• p(D) is the marginal likelihood, all possible hypotheses being considered:
p(D) =
∫
θ
p(θ)p(D|θ) dθ.
Observation error is assumed to be normally distributed with standard deviation
σ. Then the total likelihood function is given by
p(D|θ) =
T∏
i=1
N(zi|xi; θ) =
T∏
i=1
1√
2piσ2
e
−(zi−xi)2
2σ2 , (4.4)
where a Jeffreys prior distribution for σ is assumed and xi = xi(θ) for i ≥ 1.
4.3.1 Analytic Solutions
From Bayes’ formula p(θ|D) = p(θ)p(D|θ)
p(D)
, one can first determine the shape for
p(θ|D) by calculating p(θ|D) ∝ p(θ)p(D|θ) , g(θ). Notice that p(D) is a constant:
p(D) =
∫
θ
p(θ)p(D|θ) dθ.
4.3.1.1 σ uncertain
In this case, it is assumed that σ is a distribution with a Jeffreys prior.
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The following parameters were assigned independent prior distributions: (µ, d, β, σ).
But x0 = x0(σ), and xi = xi(µ, d, β, σ) for i ≥ 1. So using (4.3) with notation
∆ ,
∫∞
0
1√
2piσ2
e−
(x−z0)2
2σ2 dx, the joint probability becomes
p(θ) = p(µ)p(d)p(β)p(σ)p(x0|z0, σ) = p(µ)p(d)p(β)p(σ) 1
∆
e−
(x0−z0)2
2σ2
=
(
3∏
j=1
1√
2piσjθj
e
− (ln θj−µj)
2
2σ2
j
)
Cσ
σ
1
∆
e−
(x0−z0)2
2σ2 . (4.5)
Then using (4.5) and (4.4),
g(θ) , p(θ)p(D|θ)
=
(
3∏
j=1
1√
2piσjθj
e
− (ln θj−µj)
2
2σ2
j
)
Cσ
σ
1
∆
e−
(x0−z0)2
2σ2
T∏
i=1
1√
2piσ2
e
−(zi−xi)2
2σ2
∝
(
3∏
j=1
1
θj
e
− (ln θj−µj)
2
2σ2
j
)
1
σT+1
1
∆
T∏
i=0
e
−(zi−xi(θ))2
2σ2
, g˜(θ).
For product of small numbers, I will calculate the natural log of the product first:
ln(g˜(θ))
= −
3∑
j=1
ln θj −
3∑
j=1
(ln θj − µj)2
2σ2j
− (T + 1) ln(σ)− ln(∆)− 1
2σ2
T∑
i=0
(xi(θ)− zi)2
, G(θ). (4.6)
Thus,
p(θ|D) ∝ p(θ)p(D|θ) , g(θ) ∝ g˜(θ) = eG(θ).
Now the marginal distributions can be calculated. Remember that (θ1, θ2, θ3) =
(µ, d, β). With
H =
∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3dσdx0,
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the following marginal distributions as posterior probability are obtained:
p(θ1)
=
(∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
eG(θ) dθ2dθ3dσdx0
)
/H ∝
∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
eG(θ) dθ2dθ3dσdx0;
p(θ2)
=
(∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ3dσdx0
)
/H ∝
∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ3dσdx0;
p(θ3)
=
(∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dσdx0
)
/H ∝
∫ ∞
0
∫ 106
1
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dσdx0;
p(σ)
=
(∫ ∞
0
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3dx0
)
/H ∝
∫ ∞
0
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3dx0;
p(x0)
=
(∫ 106
1
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3dσ
)
/H ∝
∫ 106
1
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3dσ.
4.3.1.2 σ fixed
Then I also tried to set σ to be a constant, assuming information of σ can be found in
literature. I tried σ = 6.4× 104, since this is approximately the mean of the posterior
distribution for σ (see Figure 4.3 and 4.5). Then in this case, only 4 parameters need
to be studied: θ = (θ1, θ2, θ3, x0) = (µ, d, β, x0).
The following parameters are independent of each other: (µ, d, β, x0(σ)). So using
(4.3) with notation ∆ ,
∫∞
0
1√
2piσ2
e−
(x−z0)2
2σ2 dx, the prior probability becomes
p(θ) = p(µ)p(d)p(β)p(x0) = p(µ)p(d)p(β)
1
∆
e−
(x0−z0)2
2σ2
=
(
3∏
j=1
1√
2piσjθj
e
− (ln θj−µj)
2
2σ2
j
)
1
∆
e−
(x0−z0)2
2σ2 . (4.7)
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Then using (4.7) and (4.4),
g(θ) =
(
3∏
j=1
1√
2piσjθj
e
− (ln θj−µj)
2
2σ2
j
)
1
∆
e−
(x0−z0)2
2σ2
T∏
i=1
1√
2piσ2
e
−(zi−xi(θ))2
2σ2
∝
(
3∏
j=1
1
θj
e
− (ln θj−µj)
2
2σ2
j
)
T∏
i=0
e
−(zi−xi(θ))2
2σ2 , g˜(θ).
Then (4.6) becomes
ln(g˜(θ)) =−
3∑
j=1
ln θj −
3∑
j=1
(ln θj − µj)2
2σ2j
− 1
2σ2
T∑
i=0
(xi(θ)− zi)2 , G(θ). (4.8)
Then with
H =
∫ ∞
0
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3dx0,
the following marginal distributions as posterior probability are obtained:
p(θ1) =
(∫ ∞
0
∫ 1
0
∫ 1
0
eG(θ) dθ2dθ3dx0
)
/H ∝
∫ ∞
0
∫ 1
0
∫ 1
0
eG(θ) dθ2dθ3dx0;
p(θ2) =
(∫ ∞
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ3dx0
)
/H ∝
∫ ∞
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ3dx0;
p(θ3) =
(∫ ∞
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dx0
)
/H ∝
∫ ∞
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dx0;
p(x0) =
(∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3
)
/H ∝
∫ 1
0
∫ 1
0
∫ 1
0
eG(θ) dθ1dθ2dθ3.
4.3.2 MCMC Method
Evaluating the posterior distribution often requires the integration of high dimen-
sional functions (see previous section). I did not get good results from numerically
calculating these triple integrals and quadruple integrals using Matlab. Therefore
I will try the Markov Chain Monte Carlo (MCMC) method using the Metropolis-
Hastings algorithm.
The original Monte Carlo method uses random number generation to compute
integrals. To generate a Markov chain, one uses the previous sample value to generate
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the next sample value, and the transition probability is just a function of the previous
sample value. As the chain continues, the sample values get spread out over the
possible state space. The idea of discrete-time Markov chain can be generalized to a
continuous-time Markov process.
The MCMC method initially proposed by Metropolis requires the proposal dis-
tribution (or the transition probability) to be symmetric. Later this method was
modified by Hastings to work for asymmetric proposal distributions as well (Gregory
(2005)). In the simulations, to better make sure the convergence of the chains, one
should use multiple chains each starting from different initial values.
4.3.2.1 Metropolis-Hastings algorithm
The Metropolis-Hastings algorithm consists of two stages: the first stage is to generate
a candidate from the proposal distribution, and the second stage is the accept-reject
step. The proof of that the stationary distribution of the Markov chain generated by
the M-H algorithm is the target posterior distribution can be found in many material
(such as in (Gregory (2005))). Now let’s present the algorithm with details.
Metropolis-Hastings algorithm(MCMC method):
1. Initialize parameters θ.
2. Repeat
(a) Propose new values for θ as θ∗ by sampling from the proposal density
Q(θ∗, x∗1:T |θ, x1:T ), and calculate corresponding x∗1:T from ODE.
(b) With probability
min
(
Pr(θ∗, x∗1:T |z1:T )
Pr(θ, x1:T |z1:T )
Q(θ, x1:T |θ∗, x∗1:T )
Q(θ∗, x∗1:T |θ, x1:T )
, 1
)
,
set θ = θ∗; otherwise set θ = θ.
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Derived from the Bayes’ formula : Pr(θ, x1:T |z1:T ) = Pr(z1:T , x1:T |θ) Pr(θ)
Pr(z1:T )
and
Pr(θ∗, x∗1:T |z1:T ) =
Pr(z1:T , x
∗
1:T |θ∗) Pr(θ∗)
Pr(z1:T )
, where Pr(z1:T , x1:T |θ) and Pr(z1:T , x∗1:T |θ∗)
are the total likelihoods. So the acceptance probability can be rewritten as:
min
(
Pr(θ∗, x∗1:T |z1:T )
Pr(θ, x1:T |z1:T )
Q(θ, x1:T |θ∗, x∗1:T )
Q(θ∗, x∗1:T |θ, x1:T )
, 1
)
= min
(
Pr(z1:T , x
∗
1:T |θ) Pr(θ∗)
Pr(z1:T , x1:T |θ) Pr(θ)
Q(θ, x1:T |θ∗, x∗1:T )
Q(θ∗, x∗1:T |θ, x1:T )
, 1
)
,
as the marginal probability of the data Pr(z1:T ) cancels out during the calculation.
4.3.2.2 σ uncertain
In this case, it is assumed that σ is a distribution with a Jeffreys prior, then θ =
(θ1, θ2, θ3, θ4, θ5) = (µ, d, β, σ, x0(σ)). Then θis initialized as θ0 = (0.01, 0.01, 0.01, 10
3,
normrnd(z0, 10
3)) with a normrnd(z0, 10
3) > 0. Then the stochastic kernel Q(θ∗1:5|θ1:5)
is chosen such that θ∗1:4 = e
ln(θ1:4)+ε (generates only positive values) and θ∗5 = z0 +
N(0, θ∗4
2) (accepts only positive values), where ε has the multivariate normal distribu-
tion N(0,Σ2). Here Σ = (σ˜1, σ˜2, σ˜3, σ˜4), which is assumed to be Σ = (0.1, 0.1, 0.1, 10)
in the simulations. Notice that I choose a much larger value σ˜4 = 10 for σ.
Now calculate
Q(θ, x1:T |θ∗, x∗1:T )
Q(θ∗, x∗1:T |θ, x1:T )
in details first.
θ∗1:4 = e
ln(θ1:4)+ and x∗0 ∼ N(z0;σ∗) (accepts only positive values) imply that
Q(θ∗|θ) =
 4∏
j=1
1√
2piσ˜2j
e
−(ln(θ∗j )−ln(θj))2
2σ˜2
j
 e−(x∗0−z0)22σ∗2 /∫ ∞
0
e−
(x−z0)2
2σ∗2 dx.
Similarly,
Q(θ|θ∗) =
 4∏
j=1
1√
2piσ˜2j
e
−(ln(θj)−ln(θ∗j ))2
2σ˜2
j
 e−(x0−z0)22σ2 /∫ ∞
0
e−
(x−z0)2
2σ2 dx.
Then
Q(θ|θ∗)
Q(θ∗|θ) =
∫∞
0
e−
(x−z0)2
2σ∗2 dx∫∞
0
e−
(x−z0)2
2σ2 dx
e
(x∗0−z0)2
2σ∗2 −
(x0−z0)2
2σ2 .
69
Recall the likelihood function expressed in equation (4.4) and prior probability
expressed in equation (4.5), then
Pr(z1:T , x
∗
1:T |θ∗) Pr(θ∗)Q(θ|θ∗)
Pr(z1:T , x1:T |θ) Pr(θ)Q(θ∗|θ)
= exp
(
3∑
j=1
(ln(θj)− µj)2 − (ln(θ∗j )− µj)2
2σ2j
+
T∑
i=0
(
(xi − zi)2
2σ2
− (x
∗
i − zi)2
2σ∗2
))
·
(
3∏
j=1
θj
θ∗j
)( σ
σ∗
)T+1 ∫∞
0
e−
(x−z0)2
2σ2 dx∫∞
0
e−
(x−z0)2
2σ∗2 dx
· exp
(
(x∗0 − z0)2
2σ∗2
− (x0 − z0)
2
2σ2
) ∫∞
0
e−
(x−z0)2
2σ∗2 dx∫∞
0
e−
(x−z0)2
2σ2 dx
=
(
3∏
j=1
θj
θ∗j
)( σ
σ∗
)T+1
· exp
(
3∑
j=1
(ln(θj)− µj)2 − (ln(θ∗j )− µj)2
2σ2j
+
T∑
i=1
(
(xi − zi)2
2σ2
− (x
∗
i − zi)2
2σ∗2
))
,eF ,
with
F =
(
3∑
j=1
(ln(θj)− ln(θ∗j ))
)
+ (T + 1)(ln(σ)− ln(σ∗))
+
3∑
j=1
(ln(θj)− µj)2 − (ln(θ∗j )− µj)2
2σ2j
+
T∑
i=1
(
(xi − zi)2
2σ2
− (x
∗
i − zi)2
2σ∗2
)
.
Thus, the acceptance probability in each iteration (2(b)) becomes min(eF , 1).
Notice that the expression for F is closely related to expression (4.6).
In the simulation, I assume that during each step (2(a)), a new sample is obtained
by perturbing just one component of θ with equal probability. Thus, during each step,
the probability of (only) perturbing θi is
1
5
for i = 1, 2, 3, 4, 5. Therefore the stochastic
kernel Q(θ∗1:5|θ1:5) is actually chosen such that θ∗i = eln(θi)+N(0,σ˜
2
i ) with probability 1
5
for each 1 ≤ i ≤ 4 and θ∗5 = z0 +N(0, θ∗42) with probability 15 .
3× 106 iterations have been performed in each simulation. The simulation results
with the burn-in period (first 103 iterations) omitted is presented in Figure 4.3.
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4.3.2.3 σ fixed
In this case, σ = 6.4× 104 is fixed, then θ = (θ1, θ2, θ3, θ4) = (µ, d, β, x0). It is initial-
ized as θ0 = (0.01, 0.01, 0.01, normrnd(z0, 6.4×104)) with a normrnd(z0, 6.4×104) > 0.
Then the stochastic kernel Q(θ∗1:4|θ1:4) is chosen such that θ∗1:3 = eln(θ1:3)+ε (generates
only positive values) and θ∗4 = z0 + N(0, (6.4× 104)2) (accepts only positive values),
where ε has the multivariate normal distribution N(0,Σ2). Here Σ = (σ˜1, σ˜2, σ˜3),
which is assumed to be Σ = (0.1, 0.1, 0.1) in the simulations.
In this case, θ∗1:3 = e
ln(θ1:3)+ and x∗0 ∼ N(z0;σ) (accepts only positive values)
imply that
Q(θ∗|θ) =
 3∏
j=1
1√
2piσ˜2j
e
−(ln(θ∗j )−ln(θj))2
2σ˜2
j
 e−(x∗0−z0)22σ2 /∫ ∞
0
e−
(x−z0)2
2σ2 dx.
Similarly,
Q(θ|θ∗) =
 3∏
j=1
1√
2piσ˜2j
e
−(ln(θj)−ln(θ∗j ))2
2σ˜2
j
 e−(x0−z0)22σ2 /∫ ∞
0
e−
(x−z0)2
2σ2 dx.
Then
Q(θ|θ∗)
Q(θ∗|θ) = e
(x∗0−z0)2−(x0−z0)2
2σ∗2 .
Recall the likelihood function expressed in equation (4.4) and prior probability
expressed in equation (4.7), then
Pr(z1:T , x
∗
1:T |θ∗) Pr(θ∗)Q(θ|θ∗)
Pr(z1:T , x1:T |θ) Pr(θ)Q(θ∗|θ)
=
(
3∏
j=1
θj
θ∗j
)
exp
(
3∑
j=1
(ln(θj)− µj)2 − (ln(θ∗j )− µj)2
2σ2j
+
T∑
i=0
(xi − zi)2 − (x∗i − zi)2
2σ2
)
· exp
(
(x∗0 − z0)2 − (x0 − z0)2
2σ∗2
)
,eF ,
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with
F =
(
3∑
j=1
(ln(θj)− ln(θ∗j ))
)
+
3∑
j=1
(ln(θj)− µj)2 − (ln(θ∗j )− µj)2
2σ2j
+
T∑
i=1
(xi − zi)2 − (x∗i − zi)2
2σ2
.
Thus, the acceptance probability in each iteration (2(b)) becomes min(eF , 1).
Notice that the expression for F is closely related to expression (4.8).
This time, during each iteration, the probability of (only) perturbing θi is
1
4
for
i = 1, 2, 3, 4. Therefore the stochastic kernel Q(θ∗1:4|θ1:4) is actually chosen such that
θ∗i = e
ln(θi)+N(0,σ˜
2
i ) with probability 1
4
for each 1 ≤ i ≤ 3 and θ∗4 = z0+N(0, (6.4×104)2)
with probability 1
4
.
3× 106 iterations have been performed in each simulation. When σ = 6.4× 104 is
fixed, the simulation results without burn in period (first 103 iterations) is presented
in Figure 4.4. See the corresponding posterior distribution results also in Figure 4.4.
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Figure 4.3: σ random. All 3 × 106 iterations. Burn in period dropped. Red curves
indicate the prior distributions. See Figure 4.2 for prior distributions for σ and x0.
73
0 1 2 3
x 106
0.01
0.02
0.03
0.04
0.05
µ
0 1 2 3
x 106
0
0.05
0.1
0.15
0.2
d
0 1 2 3
x 106
0.05
0.1
0.15
0.2
0.25
β
0 1 2 3
x 106
3.7
3.8
3.9
4
4.1
x 106
x0
0 0.01 0.02 0.03 0.04 0.05
0
50
100
µ
µ˜ = 0.027746 and σ˜ =0.0040341
0 0.05 0.1 0.15 0.2
0
5
10
15
20
d
µ˜ = 0.089405 and σ˜ =0.018821
0 0.2 0.4 0.6 0.8 1
0
5
10
15
20
β
µ˜ = 0.15838 and σ˜ =0.023526
3.7 3.8 3.9 4 4.1
x 106
0
0.5
1
x 10−5
x0
µ˜ = 3892002 and σ˜ =41899.45
Figure 4.4: σ = 6.4× 104 fixed. All 3× 106 iterations. Burn in period dropped. Red
curves indicate the prior distributions.
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4.3.2.4 Improved MCMC
From previous simulation results (Figure 4.3 and 4.4), it shows that the chains for d
and β are not mixing as well as other parameters. Also, the chains for β and d are
highly correlated to each other (correlation coefficients are 0.9822 and 0.9683 for Fig-
ure 4.3 and 4.4 respectively). I think the strong correlation can be interpreted in the
following way. Once β (cumulative HIV-acquisition risk) increases, more susceptible
population become infected. Then in order to balance the HIV population, d (annual
rate of progression to AIDS) needs to be increased as well, so that more infections
will become sexually inactive as they develop AIDS. Therefore to get better results,
or better mixing chains for d and β, I will treat β and d as a group in the following
way.
• When σ has a Jeffreys prior:
– the probability to perturb µ is 1
5
;
– the probability to perturb both d and β is 2
5
;
– the probability to perturb σ is 1
5
;
– the probability to perturb x0 is
1
5
.
Thus, for a probability of 2
5
, a new sample θ∗ is proposed by proposing a new
value d∗ for d and a new value β∗ for β independently at the same time. If θ∗
is accepted, then both d∗ and β∗ are accepted. It is called that d and β are
grouped in this case. See corresponding results in Figure 4.5.
• When σ = 6.4× 104 is fixed:
– the probability to perturb µ is 1
5
;
– the probability to perturb both d and β is 2
5
;
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– the probability to perturb x0 is
2
5
.
See the corresponding results in Figure 4.6.
The Markov chains in Figure 4.5 and 4.6 show much better mixing in d and β,
after they have been grouped. Therefore the corresponding posterior distributions
are better than those before d and β are grouped (Figure 4.3 and 4.4).
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Figure 4.5: σ is random. All 3× 106 iterations. Burn in period dropped. Red curves
indicate the prior distributions. β and d grouped.
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4.4 Parameter Posterior Distributions
From data fitting as in Figure D.1, µ = 0.02979, d = 0.1191, and β = 0.1969
are obtained as a set of baseline parameter values. Now from Bayesian parameter
estimation (Figure 4.5 and 4.6), the posterior distributions are obtained for these
parameters. The mode and mean of these distributions are presented in Table 4.4.
The mean values are quite different from the parameter values obtained from data
fitting as in Figure D.1, especially a relative difference about |0.197−0.16||0.16| ≈ 23% for β
is observed.
Table 4.4: Parameter values comparison
Figure D.1 σ as distribution σ fixed
mean mode mean mode
µ 0.02979 0.02779 0.027 0.02803 0.0276
d 0.1191 0.09057 0.085 0.09066 0.0827
β 0.1969 0.1599 0.154 0.1604 0.15
x0 3892911.84 3.8911×106 3.89×106 3.8907×106 3.89×106
If the mode and mean are very different, the posterior PDF is too asymmetric to
be adequately summarized by a single estimate (Gregory (2005)). Here, the mode and
mean are quite close, but I still present the simulation results from two independent
Markov chains.
For each simulation, two independent Markov chains are generated. The summary
of mean, standard deviation, 95% credibility interval, and acceptance rate for each
parameter is presented in Table 4.5-4.8.
After d and β are grouped (Table 4.7 and 4.8), the posterior distributions from
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two independent Markov chains are very close to each other, and the convergence
of chains is believed. On the other hand side, the posterior distributions from two
independent Markov chains are not that close when d and β are not grouped (Table
4.5 and 4.6).
After combining d and β as a group during perturbation, although the acceptance
has been decreased from 12.13% and 8.31% (Table 4.5) to 6.51% (Table 4.7), I have
increased the probability to perturb d or β from 1
5
to 2
5
which is a compensation.
Therefore a better mixing is obtained for the Markov chains of d and β (Figure 4.5).
Table 4.5: Posterior distributions of 2 independent chains, corresponding to Figure
4.3. Total acceptance rate is 18.08% for MCMC 1 and 18.09% for MCMC 2.
MCMC 1 µ d β σ x0
Mean 0.0277 0.09193 0.1616 65202.6 3.8899×106
Standard Deviation 4.11×10−3 25.76×10−3 32.43×10−3 18.87×103 45.79×103
95% [0.02018 [0.05527 [0.1146 [37450.7 [3.7909×106
Credibility Interval 0.0358] 0.15548] 0.2407] 104879.9] 3.969×106]
Acceptance Rate 31.78% 12.13% 8.31% 2.92% 35.27%
MCMC 2 µ d β σ x0
Mean 0.02786 0.08886 0.1579 64900.5 3.8915×106
Standard Deviation 4.064×10−3 16.8×10−3 20.97×10−3 18.53×103 44.18×103
95% [0.02066 [0.05983 [0.1209 [41664.3 [3.8058×106
Credibility Interval 0.03616] 0.1216] 0.1989] 105424.4] 3.9671×106]
Acceptance Rate 31.56% 12.14% 8.33% 2.94% 35.47%
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Table 4.6: Posterior distributions of 2 independent chains, corresponding to Figure
4.4. Total acceptance rate is 21.95% for MCMC 1 and 21.73% for MCMC 2.
MCMC 1 µ d β x0
Mean 0.02775 0.0894 0.1584 3.892×106
Standard Deviation 4.034×10−3 18.82×10−3 23.53×10−3 41.9×103
95% Credibility Interval [0.02072
0.03574]
[0.05844
0.12386]
[0.1193
0.2033]
[3.8068×106
3.9655×106]
Acceptance Rate 31.83% 12.15% 12.15% 35.55%
MCMC 2 µ d β x0
Mean 0.02782 0.09601 0.1668 3.8893×106
Standard Deviation 4.139×10−3 23.59×10−3 29.47×10−3 41.99×103
95% Credibility Interval [0.02057
0.03577]
[0.05479
0.15023]
[0.1136
0.234]
[3.8051×106
3.9630×106]
Acceptance Rate 31.8% 11.56% 11.56% 35.48%
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Table 4.7: Posterior distributions of 2 independent chains, corresponding to Figure
4.5. Total acceptance rate is 16.58% for MCMC 1 and 16.6% for MCMC 2.
MCMC 1 µ d β σ x0
Mean 0.02779 0.09057 0.1599 64786.9 3.8911×106
Standard Deviation 4.143×10−3 19.94×10−3 25.15×10−3 18.53×103 44.04×103
95% [0.02062 [0.05545 [0.119 [39298.1 [3.8018×106
Credibility Interval 0.03609] 0.13109] 0.2104] 105758] 3.9601×106]
Acceptance Rate 31.45% 6.51% 6.51% 2.94% 35.5%
MCMC 2 µ d β σ x0
Mean 0.02781 0.09077 0.1602 64862.6 3.8912×106
Standard Deviation 4.194×10−3 20.34×10−3 25.52×10−3 18.77×103 44.34×103
95% [0.02061 [0.05783 [0.1155 [39039.5 [3.8085×106
Credibility Interval 0.03589] 0.13135] 0.2117] 106115.7] 3.9709×106]
Acceptance Rate 31.52% 6.5% 6.5% 2.96% 35.5%
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Table 4.8: Posterior distributions of 2 independent chains, corresponding to Figure
4.6. Total acceptance rate is 23.09% for MCMC 1 and 23.09% for MCMC 2.
MCMC 1 µ d β x0
Mean 0.02803 0.09066 0.1604 3.8907×106
Standard Deviation 4.155×10−3 19.9×10−3 24.78×10−3 41.83×103
95% Credibility Interval [0.02069
0.03632]
[0.05747
0.13002]
[0.119
0.2126]
[3.8063×106
3.9654×106]
Acceptance Rate 31.56% 6.44% 6.44% 35.51%
MCMC 2 µ d β x0
Mean 0.02804 0.09134 0.1612 3.8904×106
Standard Deviation 4.17×10−3 20.32×10−3 25.39×10−3 41.65×103
95% Credibility Interval [0.02095
0.03585]
[0.058
0.13298]
[0.1166
0.2119]
[3.8095×106
3.9651×106]
Acceptance Rate 31.49% 6.40% 6.40% 35.54%
It shows that the posterior distributions for both µ and d stays close to their
corresponding prior distributions; while the posterior distribution for β differs a lot
with its prior distribution, both in mean value and standard deviation. For β, the
standard deviation (0.02515 from Table 4.7) of the posterior distribution is much
smaller than the standard deviation (0.18981) of the prior distribution, providing a
sharper estimation for β.
The little difference between prior and posterior distributions for µ and d implies
that the data used is not very informative. Therefore the posterior distributions are
mainly determined by the information provided by the prior distributions.
Notice that β = 1− (1− ba)n is a composite parameter. Information on ba and n
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can both be found in literature (Boily et al. (2009),Wawer et al. (2005)). In this study,
a posterior distribution for β (mean = 0.1599 and standard deviation = 0.02515 from
Table 4.7) is also obtained, which can be a supplement to the previous HIV studies.
σ assumed with a Jeffreys prior, or assumed to be a constant, give similar posterior
distributions for x0 (as well as µ, d, and β), and standard deviation for the former is
slightly larger. This is because, the posterior distribution of σ adds a diffusive effect
on x0(σ) compared with when σ fixed as a constant.
From the simulation results, it is believed that σ ∈ [39298, 105758] (95% CI from
Table 4.7) gives a good approximation for the observation error in HIV population
in South Africa. Correspondingly, it is believed that x0 ∈ [3.8018× 106, 3.9601× 106]
(95% CI) gives a good approximation for the actual HIV population in 2001.
4.5 Model Validation
Because the consecutive values generated generated by a MCMC simulation are
correlated, they provide less accurate estimates than independent samples. One mea-
sure of the accuracy of the estimate and how well the chain is mixing is the effective
sample size (ESS).
The ESS is equal to
ESS =
N
1 + 2
∞∑
k=1
ρk(θ)
,
where N is the number of posterior samples, ρk is the autocorrelation at lag k. The
infinite sum is often truncated when ρk < 0.05 (ESS (2014),Kass et al. (1998)). I will
use the sample autocorrelation function to estimate the ESS:
ρk(θj) =
N−k∑
i=1
[θj(i)− µ˜] · [θj(i+ k)− µ˜]
N∑
i=1
[θj(i)− µ˜]2
, k = 1 · · ·N − 1.
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Here µ˜ is the sample mean of θj, and
N∑
i=1
[θj(i)− µ˜]2 is the sample variance of θj. The
sum will be truncated when ρk < 0.01.
Table 4.9: Effective Sample Size, when d and β are not grouped.
number of samples µ d β σ x0
104 6 5 7 44 75
105 48 5 4 252 489
106 − 103 422 21 22 2610 4282
3× 106 − 103 1431 24 24 2154 624
Table 4.10: Effective Sample Size, when d and βd are grouped.
number of samples µ d β σ x0
104 19 10 10 41 59
105 39 131 123 302 388
106 − 103 404 935 877 3095 3154
3× 106 − 103 1298 2639 2326 7873 9081
Then for Figure 4.3 and 4.5, the corresponding results for ESS for each parameter
are presented in Table 4.9 and 4.10 respectively. I have calculated the ESS given
different number of samples. Originally, only 106 iterations were performed in each
iteration. After dropping the first 103 iterations, the ESS of some parameters (µ, d
and β in Table 4.10) can be less than 1000. Then I decided to run 3× 106 iterations
to get a better result. Then after dropping the first 103 iterations, the ESS for each
parameter becomes 1298, 2639, 2326, 7873, and 9081, all greater than 1000 (ESS
(2014)).
Also, notice that after d and β are grouped, the ESS for d and β have been
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increased dramatically. This is consistent with the better mixing in Markov chains
that have been observed. ESS given 3×106−103 samples is expected to greater than
ESS given 106− 103 samples. However, for σ and x0 in Table 4.9, this is not the case.
I think this may be due to the fact that ESS can only be estimated but calculated
exactly.
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Figure 4.7: From year 2003 to 2011, 1000 samples of simulated HIV population
observations are plotted for each year. The mean of the simulated observations is
plotted in yellow for each year. The true observation is plotted in red for each year.
For model validation, 1000 independent samples are drawn from the posterior
distributions, for all the parameters. Then for each sample of parameter values µ,
d, β and x0, the ODE (4.1) is solved and the solutions saved (HIV population from
year 2001 to 2011). Finally for each year (2003 to 2011), simulated observations
are generated with the ODE solutions as mean and sample values of σ as standard
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deviation. These simulated observations for all 1000 samples are plotted in Figure
4.7, compared with the true observation from South Africa (Table A.1).
The mean of simulated observations from year 2003 to 2011 is
106 × [4.0344, 4.1087, 4.1843, 4.2610, 4.3384, 4.4161, 4.4938, 4.5709, 4.6471],
while the true observations from year 2003 to 2011 is
106 × [4.1198, 4.0816, 4.0408, 4.1815, 4.1985, 4.2632, 4.3349, 4.4582, 4.5106].
Not only the simulated observations contains the true observations from data, the
mean of the simulates observations are very close to the true observations. This
validates that the estimations are consistent with the true observations.
I think the Bayesian parameter estimation provides more reliable information for
the parameters than the least square fitting (or similar approaches) does, as it provides
distributions for each parameter, and it takes the observation error in HIV population
into account. The posterior distributions give possible regions for parameter values
such as 95% credibility intervals, also the the probability for a parameter to equal
some specific value.
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Chapter 5
CONCLUSION AND FUTURE WORK
In Chapter 2, the study was focused on six different effectiveness indicators for HIV
interventions. Four of them are dimensionless (PI , aII , FI , FˆI) and two depend on the
population size (CI , CˆI). These indicators were defined for the HIV model with PrEP
interventions. Then I studied their dynamics at the beginning of the interventions,
and their asymptotic behaviors when the ODE system approaches the steady state.
I mainly looked at how these indicators depend on the parameters. The parameters
can be divided into two groups, the ones that are related to HIV infection (ba, n, µ,
d); the ones that are related to the epidemic (P ), or effectiveness and implementation
of PrEP (αs, αi, k1, θ).
To intuitively show the dependence of the indicators on the parameters, by the
end of this chapter, some results are presented from sensitivity analysis. I chose 10
years to illustrate the short term dynamics at the beginning of the intervention, and
100 years to illustrate the long time dynamics approaching the steady state. Despite
all the discrepancies one can see, I also observed the similarity between indicators.
Among the intervention parameters, PrEP coverage (k) and PrEP efficacies per act
(αs and αi) express strong positive correlation with all the indicators in a short
term. It remains significant in a long term for all outcomes. This confirms that
PrEP coverage and protection level are critical to the intervention success regardless
which qualitative metric is used. The prevalence (PI) and the annual incidence (aII)
indicators express almost the same sensitivity to all parameters. Therefore they
should have consistent projections when evaluating the impact of the intervention.
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Minimal efficacy thresholds of 20% or higher are often included in the design of
RCTs and similar levels of effectiveness is expected when interventions are modeled
at population level (Dimitrov et al. (2013); Grant et al. (2010)). Other studies imply
that 50% biological efficacy is needed to guarantee significant public-health impact.
It has been shown that the widely used evaluation metrics may disagree over practical
intervals of time (Figure 2.5). A reduction in HIV incidence at pre-specified levels
seems most realistic as an intervention goal but it is not easy to be estimated in the
population. In contrast, a reduction in HIV prevalence is easier to be recorded but
more difficult to be achieved in a short term. The reduction in the number of new
HIV infections, which is the most popular public-health metric, projects strong PrEP
effectiveness initially but grows slower than the other indicators over time. Public-
health officials who consider PrEP to be integrated in HIV prevention programs should
base their decision on a complex of quantitative metrics.
In Chapter 3, analytic study and bifurcation simulations have been done on models
with 3 different entrance rates: constant recruitment, linear recruitment, and logistic
recruitment. Analytic results haven been summarized for models without intervention
in Section 3.1, Table 3.2. For models with interventions, similar summary based on
both analytic study and bifurcation simulations is presented in Section 3.2, Figure
3.3.
Note that the trajectories of the models with constant and logistic recruitment
are bounded while the linear recruitment allows for unbounded solutions. As the HIV
risk (β) increases, the model with constant recruitment switches from infection-free
to endemic steady state while the model with logistic recruitment equilibrium goes
from infection-free to endemic equilibrium and further to population extinction. The
trajectories of the linear model follow a similar pattern as the logistic recruitment
model: from unbounded infection-free through unbounded endemic state to popu-
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lation extinction. However, the transition (bifurcation) points where the behavior
changes occur are different for the three models. As a result the projected long-term
prevalence with each of the three models differ for epidemic conditions with R0 greater
than one. What in common for all the three models is when R0 < 1, the status of
the population approaches infection free; when R0 > 1, the status of the population
approaches coexistence or extinction.
I also looked at influence of different recruitment on the PrEP effectiveness. As a
result the simulations of the HIV epidemics with the three models over 70 years show
large discrepancies in population size and epidemic distribution under identical initial
conditions and forces of infection. The projected HIV prevalence varies from 25%
when constant recruitment is assumed and 42% when linear recruitment is assumed.
In addition, significant difference in the reduction in HIV prevalence and incidence
(almost 20%) is predicted when 50% effective PrEP is used by 20% of the population.
Over the entire simulated period, linear recruitment provides the most optimistic
estimates of the PrEP effectiveness in terms of prevalence reduction while constant
recruitment predicts larger fraction of infections prevented.
It can be argued that regardless of the differences in the dynamic behavior all
three models agree in their effectiveness projections over 20-30 years which is the usual
period over which the intervention are evaluated. However, often the models are run
for extended periods in order to simulate “mature” epidemics and the intervention is
introduced afterwards. The key message of this analysis is that the way recruitment is
incorporated in the models impacts the HIV epidemic and may have significant effect
on the projected effectiveness of different HIV intervention in a short and long term.
Demographic data, including statistics on births and age-specific mortality, should be
used to inform the modeling mechanisms before HIV prevention is considered.
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The models I studied are based on many simplified assumptions, presented in
Section 2.1.1. There are many more practical models in literature considering more
complicated models when age structure, population heterogeneity, drug resistance,
and more are taken into account. However, to illustrate how different evaluation
indicators and recruitment rates can affect the modeling results, it is better to start
with the simplified model. The simplicity of the model makes these differences more
significant. Modelers can refer to this and be aware of the possible different choices
regarding the intervention evaluation methods and entrance rates. These different
choices probably will also affect more complicated models at various levels.
In the previous chapters, the parameter values (β, µ, d) are either chosen from
literature or obtained from fit model to data using an approach similar to least square
fitting. In Chapter 4, to obtain more comprehensive information on parameter val-
ues, Bayesian inference is applied to fit the HIV model without intervention to South
Africa HIV data (Table A.1). Bayesian parameter estimation eventually provide a
distribution for each parameter. Evaluating the posterior distribution often requires
the integration of high-dimensional functions, which is usually difficult to calculate
numerically. However, the Markov Chain Monte Carlo (MCMC) method using the
Metropolis-Hastings algorithm can be applied to approximate the posterior distribu-
tion, which is not difficult to implement. The convergence of the Markov chains is
believed in this study. These chains provided good approximations for the posterior
distributions of the key parameters (β, µ, d). The mean, standard deviation, and
95% confidence interval for the posterior distribution of each parameter can be easily
summarized.
The little difference between prior and posterior distributions for µ and d implies
that the data used is not very informative. Therefore the posterior distributions are
mainly determined by the information provided by the prior distributions. Notice
91
that β = 1− (1− ba)n is a composite parameter, which can not be measured directly.
Information on ba and n can both be found in literature (Boily et al. (2009),Wawer
et al. (2005)). In this study, a posterior distribution for β (mean = 0.1599 and
standard deviation = 0.02515 from Table 4.7) is obtained, which can be a supplement
to the previous HIV studies.
Bayesian inference can also be applied in model selection (Gregory (2005); Raftery
(1995); Toni et al. (2009)). If more data is available, the three models with different
entrance rates may be differentiable.
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Figure A.1: Initial guess for capacity K is approximated by 2×(South Africa popu-
lation at year 2001), because of the turning point observed at year 2001.
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Proof for Proposition 3.1.1.1:
Proof. Positivity and boundedness of solutions can be easily proved. Then periodic
solutions can be excluded by Dulacs Criteria: ∂
∂S
P
SI
+ ∂
∂I
Q
SI
= − Λ
S2I
< 0.
(3.1) has two possible steady states E0 = (
1
µ
Λ, 0) and E∗ = ( 1
β−dΛ,
1
β−d(R0−1)Λ),
with notation R0 =
β
µ+d
.
Eigenvalues λ1 = −µ < 0 and λ2 = (µ+ d)(R0− 1) for E0 imply that E0 is stable
when R0 < 1 and unstable when R0 > 1.
Notice that E∗ (positive steady state) exists if and only if R0 > 1. Then cor-
responding eigenvalues λ1 + λ2 = (µ + d)(1 − R0 − µµ+d) < 0 and λ1 × λ2 =
(µ+ d)[β(R0 − 1)2 + µR0(R0 − 1)] > 0 imply that when exists E∗ is stable.
Finally by Poincare´-Bendixson theorem, about global stability we have the fol-
lowing results:
• when R0 < 1, E0 is globally stable and E∗ does not exist;
• when R0 > 1, E∗ is globally stable and E0 is unstable.
Proof for Proposition 3.1.2.1:
Proof. The positivity of the solutions can be easily proved. Then dN
dt
= dS
dt
+ dI
dt
=
rN − µS − (µ + d)I = (r − µ)N − dI ≤ (r − µ)N implies that N(t) → 0 extinction
if r < µ. Next we study the cases when r > µ. Further if we assume β > d and
µ+ d > r, by Proposition 3.1.2.2, we have the following results:
• when β < µ+ d, (S(t), I(t))→ (∞, 0) unbounded infection free.
• when µ+ d < β < (µ+d)d
µ+d−r , (S(t), I(t))→ (∞,∞) unbounded endemic.
• when β > (µ+d)d
µ+d−r , (S(t), I(t))→ (0, 0) extinction.
Proof for Proposition 3.1.2.2:
Proof. Assume that r > µ, β > d and µ + d > r. If s(0) ∈ [0, 1), then lim
t→∞
s(t) = 1
( lim
t→∞
i(t) = 0) if r
β−d ≥ 1; limt→∞ s(t) =
r
β−d ( limt→∞
i(t) = 1 − r
β−d) if
r
β−d < 1. Further,
we can study N(t) from dN
dt
, and I(t) from dI
dt
. In each case, for different parameter
values, we have lim
t→∞
N(t) = 0 or lim
t→∞
N(t) =∞; and lim
t→∞
I(t) = 0 or lim
t→∞
I(t) =∞:
• when β < µ+ d, (S(t), I(t))→ (∞, 0) with (s(t), i(t), N(t))→ (1, 0,∞);
• when µ+d < β < r+d, (S(t), I(t))→ (∞,∞) with (s(t), i(t), N(t))→ (1, 0,∞);
• when r + d < β < (µ+d)d
µ+d−r , (S(t), I(t)) → (∞,∞) with (s(t), i(t), N(t)) →
( r
β−d , 1− rβ−d ,∞);
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• when β > (µ+d)d
µ+d−r , (S(t), I(t))→ (0, 0) with (s(t), i(t), N(t))→ ( rβ−d , 1− rβ−d , 0).
Proof for Proposition 3.1.3.1:
Proof. Periodic solutions can be excluded by Dulac’s Criteria: ∂
∂S
( P
SI
) + ∂
∂S
( Q
SI
) =
− r
K
( 1
S
+ 1
I
)− r
S2
(1− S+I
K
) < 0.
(3.1) has three possible steady states E00 = (0, 0), E01 = (
r−µ
r
K, 0) and E∗ =
r−µ−d(1− 1
R0
)
r
K( 1
R0
, R0−1
R0
), with notation R0 =
β
µ+d
.
Similar to Proposition 3.1.2.1, we can show that N(t)→ 0 if r < µ, also E01 and
E∗ both do not exist. So next we will study the cases when r > µ. Further we assume
β > d and µ+ d > r.
Eigenvalues λ1 = −(r − µ) < 0 and λ2 = β − (µ + d) for E01 imply that when
exists E01 is stable if R0 < 1, and unstable if R0 > 1.
Notice that E∗ (positive steady state) exists if and only if R0 > 1 and r >
µ + d(1 − 1
R0
) (⇔ R0r + d > β > µ + d ⇒ R0r > µ). Eigenvalues λ1 + λ2 =
−[r−µ−d(1− 1
R0
)]−(1− 1
R0
)(β−d) < 0 and λ1 ·λ2 = [r−µ−d(1− 1R0 )][β−(µ+d)] > 0
for E∗ imply that E∗ is stable when exists.
Thus,
• when r < µ, E00 is (globally) stable, while E01 and E∗ do not exist.
• When r > µ(assume β > d and µ+ d > r),
– if β < µ+ d(R0 < 1), E01 is stable and E
∗ does not exist;
– if R0r+d > β > µ+d(R0 > 1), E
∗ exists and is stable and E01 is unstable;
– if β > R0r + d(R0 > 1), E01 is unstable and E
∗ does not exist.
This can be simplified as: when r > µ, β > d, and µ+ d > r,
• if β < µ+ d, E01 is stable and E∗ does not exist;
• if µ+ d < β < (µ+d)d
µ+d−r , E
∗ exists and is stable and E01 is unstable;
• if β > (µ+d)d
µ+d−r , E01 is unstable and E
∗ does not exist.
Next we combine the local stability results for E00 from Proposition 3.1.3.2.
Finally by Poincare´-Bendixson theorem, about global stability we have the fol-
lowing conclusions(assume r > µ, β > d, and µ+ d > r):
• when β < µ+ d, (S(t), I(t))→ E01 = ( r−µr K, 0) the infection free steady state,
while E00 is unstable and E
∗ does not exist;
• when µ + d < β < (µ+d)d
µ+d−r , (S(t), I(t)) → E∗ =
r−µ−d(1− 1
R0
)
r
K( 1
R0
, R0−1
R0
) the
endemic steady state, while E00 and E01 are unstable;
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• when β > (µ+d)d
µ+d−r , (S(t), I(t)) → E00 = (0, 0) the extinction steady state, while
E01 and E
∗ are unstable.
Proof for Proposition 3.1.3.2:
Proof. There are four possible steady states for (3.2): E1 = (1, 0), E2 = (
r
β−d , 0),
E3 = (1,
r−µ
r
K), and E4 = (
1
R0
,
r−µ−d(1− 1
R0
)
r
K). Notice that E3 and E4 are equivalent
with E01 and E
∗ respectively, while E1 and E2 are both corresponding to E00. So we
only study E1 and E2 here, and we assume r > µ, β > d, and µ+ d > r.
Eigenvalues λ1 = β − d− r and λ2 = r − µ > 0 for E1 imply that E1 is unstable.
Eigenvalues λ1 = d + r − β and λ2 = −µ+dβ−d(β − d − R0r) for E2 imply that E2 is
stable if β > d + r and β > d+ R0r. Thus, E00 is stable if β > max{d+ r, d + R0r}
with (s(t), i(t), N(t))→ ( r
β−d , 1− rβ−d , 0) and unstable if β < max{d+ r, d+R0r}.
Then,
• when R0 < 1(β < µ+ d), E00 is unstable since β < d+ r;
• when R0 > 1(β > µ+d), E00 is stable if β > d+R0r and unstable if β < d+R0r.
This can be simplified to be:
• if β < (µ+d)d
µ+d−r , E00 is unstable;
• if β > (µ+d)d
µ+d−r , E00 is stable.
Proof for Proposition 3.2.1.1:
Proof. Positivity and boundedness of solutions can be easily proved. Then dS
p
dt
≤
kΛ − µSp implies lim sup
t→∞
Sp ≤ kΛ
µ
and dS
dt
≤ (1 − k)Λ − µS implies lim sup
t→∞
S ≤
(1−k)Λ
µ
. Therefore dN
dt
= dS
p
dt
+ dS
dt
+ dI
dt
= Λ − µN − dI ≥ Λ − (µ + d)N implies
lim inf
t→∞
N ≥ Λ
µ+d
. Then in long term S
N
≤ (1−k)(µ+d)
µ
, S
p
N
≤ k(µ+d)
µ
, and so dI
dt
≤
I
[
β (1−k)(µ+d)
µ
+ (1− αs)β k(µ+d)µ − (µ+ d)
]
= I (µ+d)
2
µ
[
β 1−k
µ+d
+ (1− αs)β kµ+d − µµ+d
]
=
I (µ+d)
2
µ
(
R0 − µµ+d
)
. Now if R0 <
µ
µ+d
, then because of the positivity of the solution,
we know lim
t→∞
I = 0. Then combine with equations in (3.3), we know lim
t→∞
Sp = kΛ
µ
and lim
t→∞
S = (1−k)Λ
µ
. Thus, global stability of infection free steady state E0 =
(kΛ
µ
, (1−k)Λ
µ
, 0) under condition R0 <
µ
µ+d
is proved.
For local stability of E0, we look the corresponding eigenvalues λ1 = −µ < 0,
λ2 = −µ < 0 and λ3 = (µ + d)(R0 − 1). Therefore, E0 is stable when R0 < 1 and
unstable when R0 > 1.
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Now assume that β > d. For F (I) over [0, Λ
d
], the following results hold: F (0) = 0,
F (Λ
d
) = −µ < 0, F ′(0) = (µ+d)(R0−1), and F ′′(I) = −2k(1− αs)β[(1− αs)β − d]Λ
2
[Λ− dI + (1− αs)βI]3
−2(1− k)β(β − d)Λ
2
[Λ− dI + βI]3 =
2k(1− αs)β[d− (1− αs)β]Λ2
{Λ− [d− (1− αs)β]I}3 −
2(1− k)β(β − d)Λ2
[Λ + (β − d)I]3 . Fur-
ther if (1 − αs)β ≥ d then F ′′(I) < 0 over[0, Λd ]; else if (1 − αs)β < d then F ′′(I)
increases over [0, Λ
d
]. Thus, F is either concave down, or concave up, or changes from
concave down to concave up over [0, Λ
d
]. Now if R0 > 1, then F (0) = 0, F
′(0) > 0 and
F (Λ
d
) < 0 implies a unique solution of F (I) = 0 over [0, Λ
d
], because of the concavity
of F (I) over [0, Λ
d
]. Else if R0 < 1, then F (0) = 0, F
′(0) < 0 and F (Λ
d
) < 0 implies no
solution of F (I) = 0 over [0, Λ
d
], because of the concavity of F (I) over [0, Λ
d
]. Thus,
assume that β > d, then we have a unique E∗ if R0 > 1 and no E∗ if R0 < 1.
Notice that Because of the complexity of the expressions, we will not express the
positive steady state explicitly. Now assume that R0 =
(1−αsk)β
µ+d
> 1. The Jacobian
matrix for a positive steady state can be expressed as:
J =
[−(1− αs)βi∗(1− p∗)− µ (1− αs)βp∗i∗ −(1− αs)βp∗(1− i∗)
βs∗i∗ −βi∗(1− s∗)− µ −βs∗(1− i∗)
[(1− αs)β − (µ+ d)]i∗ [β − (µ+ d)]i∗ −(µ+ d)i∗
]
, with p∗ =
Sp∗
N∗ , s
∗ = S
∗
N∗ , and i
∗ = I
∗
N∗ . With P =
[
1 −1 −1
0 1 0
0 0 1
]
, J is similar to
H = P−1JP =
[ −µ 0 d
βs∗i∗ −µ− βi∗ −βs∗
[(1− αs)β − (µ+ d)]i∗ αsβi∗ −(1− αs)βi∗
]
.
Then J and H share the same eigenvalues. Let λ be an arbitrary eigenvalue, then we
can eventually get the characteristic equation
1
d
(λ+ µ)[λ+ (1− αs)βi∗] + αsβ
2i∗s∗
d
· λ+ µ+ di
∗
λ+ µ+ βi∗
+ [(1− αs)β − (µ+ d)]i∗ = 0.
Now plug λ = u + iv in the characteristic equation, and extract the imaginary
part we obtain:
v
d
[2u+ µ+ (1− αs)βi∗ + αsβ
2(β − d)i∗2s∗
(u+ µ+ βi∗)2 + v2
] = 0.
Notice that β−d > 0 since R0 > 1, then v 6= 0 implies u < 0. Otherwise v = 0 implies
f(λ) = f(u) , 1
d
(u+µ)[u+(1−αs)βi∗]+αsβ
2i∗s∗
d
· u+ µ+ di
∗
u+ µ+ βi∗
+[(1−αs)β−(µ+d)]i∗
and f(u) increases over [0,∞) since β > d. Then
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f(0) =
1
d
µ(1− αs)βi∗ + αsβ
2i∗s∗
d
· µ+ di
∗
µ+ βi∗
+ [(1− αs)β − (µ+ d)]i∗
>
1
d
µ(1− αs)βi∗ +
αsβ
2i∗ (1−k)d
β
d
· d
β
+ [(1− αs)β − (µ+ d)]i∗
=
1
d
µ(1− αs)βi∗ + αs(1− k)di∗ + (1− αs)βi∗ − (µ+ d)i∗
= {µ+ d
d
[(1− αs)β − d] + αs(1− k)d}i∗.
Notice that s∗ = S
∗
N∗ =
Λ(1−k)
Λ+(β−d)I∗ >
Λ(1−k)
Λ+(β−d) Λ
d
= (1−k)d
β
. I hope to show that f(0) > 0
and so f(u) > 0 over [0,∞), and further f(u) = 0 can only have negative solutions.
But it seems I can only show this given extra condition µ+d
d
[(1−αs)β−d]+αs(1−k)d >
0.
I believe in f(0) > 0 without this extra condition, which needs to be further
studied in future.
Proof for Proposition 3.2.2.1:
Proof. The positivity of the solutions can be easily proved. Then similar to Proposi-
tion 3.1.2.1, we can show that the unique steady state E = (0, 0, 0) is globally stable
if r < µ. Next we will study the cases when r > µ.
From Proposition 3.2.2.2, we know when β > d, there is no periodic solution for
the reduced system (3.4) , and (3.5), and therefore E1 = (k, 0) is globally stable
when (1 − k)β + k(1 − αs)β < d + r, while E2 = (p∗, i∗) is globally stable when
(1 − k)β + k(1 − αs)β > d + r. Then by (3.6), the total population N(t) either
approaches 0 when r − µ − d lim
t→∞
i(t) < 0, or blows up when r − µ − d lim
t→∞
i(t) >
0. Similarly by (3.7), the infected population I(t) either approaches 0 when β(1 −
lim
t→∞
p(t) − lim
t→∞
i(t)) + (1 − αs)β lim
t→∞
p(t) − (µ + d) < 0, or blows up when β(1 −
lim
t→∞
p(t)− lim
t→∞
i(t)) + (1− αs)β lim
t→∞
p(t)− (µ+ d) > 0.
Thus, periodic solutions for (3.3) do not exist when β > d.
Proof for Proposition 3.2.2.2:
Proof. Positivity of solutions for the transformed system can be easily checked. Fur-
ther,
dp
dt
+
di
dt
= kr − rp− βpi+ αspi+ dpi+ (β − d)i− ri− αsβpi− (β − d)i2
= kr − r(p+ i)− βpi− (β − d)pi+ (β − d)i− (β − d)i2
= kr − r(p+ i)− βpi+ (β − d)i[1− (p+ i)].
Then at p + i = 1, d(p+i)
dt
= −r + kr − βpi = −r(1 − k) − βpi < 0 implies that
(p+ i)(t) ≤ 1 for t > 0 given that (p+ i)(0) ≤ 1.
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The periodic solutions for the reduced system (therefore for the transformed sys-
tem) can be excluded by Dulac’s Criteria: ∂
∂p
(X
pi
) + ∂
∂i
(Y
pi
) = − kr
p2i
− β−d
p
< 0, when
given β − d > 0.
For the reduced system, there are possibly several steady states: E1 = (k, 0)(always
exists), E2 = (p
∗, i∗)(positive steady state(s), existence depends on parameter values).
For E1, we have eigenvalues λ1 = −r < 0 and λ2 = (1− αsk)β − (d+ r). Then if
(1− αsk)β < (d+ r), E1 is locally stable; if (1− αsk)β > (d+ r), E1 is unstable.
For E2, we have Ap
∗2 + Bp∗ + C = 0 and i∗ = 1 − αsβp∗+r
β−d , with A = αsβ[(1 −
αs)β−d], B = −{(β−d− r)[(1−αs)β−d]+(β−d)r}, and C = (β−d)kr. If further
0 < p∗ < 1 and 0 < i∗ < 1, then (p∗, i∗) exists as a positive steady state. (There may
be more than one positive steady state.)
Notice that p∗ ∈ (0, β−(d+r)
αsβ
) and i∗ ∈ (0, β−(d+r)
β−d ). So we assume that β > d + r.
Denote F (p) = Ap2 + Bp + C, then we have the following results for F (p) over
(0, β−(d+r)
αsβ
): F (0) = (β − d)kr > 0, and F (β−(d+r)
αsβ
) = − (β−d)r
αsβ
[(1 − kαs)β − (d + r)].
Now if (1 − kαs)β > d + r, then F (0) > 0 and F (β−(d+r)αsβ ) < 0 implies a unique
solution of F (p) = 0 over (0, β−(d+r)
αsβ
), because F (p) is a parabolic function.
Now look at the case when (1−kαs)β < d+r(⇒ (1−αs)β−d < r). If (1−αs)β ≤ d,
then F (0) > 0 and F (β−(d+r)
αsβ
) > 0 implies no solution of F (p) = 0 over (0, β−(d+r)
αsβ
),
because F (p) is linear or concave down. If (1 − αs)β > d, then F (p) is concave up
and attains its minimum at pˆ = β−(d+r)
2αsβ
+ (β−d)r
2αsβ[(1−αs)β−d] >
β−(d+r)
2αsβ
+ (β−d)r
2αsβr
> β−(d+r)
αsβ
.
Therefore if (1− αs)β > d, then F (0) > 0 and F (β−(d+r)αsβ ) > 0 implies no solution of
F (p) = 0 over (0, β−(d+r)
αsβ
), because F (p) is decreasing over (0, β−(d+r)
αsβ
).
Together if β ≥ d+ r, a unique solution of F (p) = 0 exists over (0, β−(d+r)
αsβ
) when
(1− kαs)β > d+ r and no solution exists over (0, β−(d+r)αsβ ) when (1− kαs)β < d+ r.
Next, we can show that E2 when exists, is stable. Notice that the existence of E2
requires (1− αsk)β > (d+ r) (when E1 is unstable). We have
kr − rp∗ − [(1− αs)β − d]p∗i∗ = 0
⇒ −r − [(1− αs)β − d]i∗ = −kr
p∗
, −[(1− αs)β − d]p∗ = −kr − rp
∗
i∗
,
and
β − (d+ r)− αsβp∗ − (β − d)i∗ = 0.
And we have the following Jacobian matrix for E2:
J(E2) =
∣∣∣∣ −r − [(1− αs)β − d]i∗ −[(1− αs)β − d]p∗−αsβi∗ −(β − d)i∗ + β − (d+ r)− αsβp∗ − (β − d)i∗
∣∣∣∣ .
Then
J(E2) =
∣∣∣∣ −krp∗ −kr−rp∗i∗−αsβi∗ −(β − d)i∗
∣∣∣∣ .
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The corresponding eigenvalues satisfy
λ1 + λ2 = −kr
p∗
− (β − d)i∗ < 0,
and
λ1 · λ2 = kr
p∗
(β − d)i∗ − αsβ(kr − rp∗).
Further
λ1 · λ2 = kr
p∗
(β − d)(1− αsβp
∗ + r
β − d )− αsβ(kr − rp
∗)
=
r
p∗
[k(β − d− αsβp∗ − r)− αsβ(k − p∗)p∗]
=
r
p∗
[αsβp
∗2 − 2αsβkp∗ + k(β − d− r)].
We next conclude λ1 · λ2 > 0 from f(p∗) = αsβp∗2 − 2αsβkp∗ + k(β − d− r) > 0.
We know f(p∗) attains the minimum value f(k) at p∗ = k. Now it is sufficient to
show that f(k) > 0. Since (1− αsk)β > (d+ r)⇒ β − d− r > αskβ, then
f(k) = αsβk
2 − 2αsβk2 + k(β − d− r)
= k(β − d− r)− αsβk2
> kαskβ − αsβk2
= 0.
Thus, we have proved that E2 when exists (require (1−αsk)β > (d+r)), is stable.
Further since (1 − αsk)β > (d + r) implies β > d (no periodic solutions) and E1 is
unstable, then E2 when exists is globally stable.
If (1 − αsk)β < (d + r), then E1 is stable and E2 does not exist. Further β > d
implies no periodic solutions, therefore we conclude that E1 is globally stable provided
that (1− αsk)β < (d+ r) and β > d.
Proof for Proposition 3.2.3.1:
Proof. The invariance of the biologically region can be easily proved.
Then similar to Proposition 3.1.2.1, we can show that the extinction steady state
E00 is globally stable if r < µ.
From now on, we assume r > µ. About the eigenvalues for E01, we have λ1 +λ2 =
−r < 0, λ1 × λ2 = µ(r − µ) > 0 and λ3 = (µ + d)(R0 − 1). Therefore E01 is stable
when R0 < 1 and unstable when R0 > 1.
From Proposition 3.2.3.2, we know when r > µ, then extinction steady state is
stable if (1− k)β + k(1−αs)β > d+ r and unstable if (1− k)β + k(1−αs)β < d+ r;
further when β > µ+ d, the positive steady state exists if R0 > 1 and i
∗ = I
∗
N∗ <
r−µ
d
and does not exist if R0 < 1 or i
∗ = I
∗
N∗ >
r−µ
d
.
Proof for Proposition 3.2.3.2:
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Proof. For (3.8), there are possibly several steady states: E1 = (k, 0, 0)(always exists),
E2 = (p
∗, i∗, 0)(existence depends on parameter values), E3 = (k, 0,
r−µ
r
K), and E4 =
(p∗, i∗, N∗)(existence depends on parameter values). Notice that E3 is equivalent with
E01 = (k
r−µ
µ
K, (1 − k) r−µ
µ
K, 0) for (3.3), and E4 is equivalent with positive steady
state E∗ for (3.3) if exists, while E1 and E2 are both corresponding to E00 = (0, 0, 0)
for (3.3). We will assume r > µ.
For E1, we have eigenvalues λ1 = −r < 0, λ2 = (1 − αsk)β − (d + r), and
λ3 = r − µ > 0. So E1 is unstable.
For E2, we have Ap
∗2 + Bp∗ + C = 0 and i∗ = 1 − αsβp∗+r
β−d , with A = αsβ[(1 −
αs)β−d], B = −{(β−d− r)[(1−αs)β−d]+(β−d)r}, and C = (β−d)kr. If further
0 ≤ p∗ ≤ 1 and 0 ≤ i∗ ≤ 1, then (p∗, i∗, 0) exists as a steady state. This is similar to
the case E2 = (p
∗, i∗) in Proposition 3.2.2.2(with linear entrance rate).
For E4, we have Ap
∗2 +Bp∗+C = 0, i∗ = β−µ−d−αsβp
∗
β
, N∗ = r−µ−di
∗
r
K, with A =
αs(1−αs)β, B = −[(1−αs)(β−µ−d)+µ+kαsd], and C = kdβ−µ−dβ +kµ. Therefore,
positive steady states may exist but too complicated to be expressed explicitly.
Notice that i∗ ∈ (0, r−µ
d
) and p∗ ∈
(
β−(µ+d)− r−µ
d
αsβ
, β−(µ+d)
αsβ
)
. So we assume that
β > µ + d and r > µ so that E4 may exist as an endemic steady state. Denote
F (p) = Ap2 + Bp + C, then we have the following results for F (p) over (0, β−(µ+d)
αsβ
):
F (0) = k(µ+d)(β−d)
β
> 0, and F (β−(µ+d)
αsβ
) = −µ(µ+d)
αsβ
(R0 − 1). Now if R0 > 1, then
F (0) > 0 and F (β−(µ+d)
αsβ
) < 0 implies a unique solution of F (p) = 0 over (0, β−(µ+d)
αsβ
),
because F (p) is a parabolic function. Further if the solution p∗ > β−(µ+d)−
r−µ
d
αsβ
, then
there exists a unique E2. Thus, if β > µ + d and r > µ, then there is a unique E2
when R0 > 1 and p
∗ > β−(µ+d)−
r−µ
d
αsβ
(⇔ i∗ < r−µ
d
).
Now look at the case when R0 < 1(⇒ β < µ+d1−kαs ). F (p) is concave up and attains
its minimum at pˆ = β−(µ+d)
2αsβ
+ µ+kαsd
2αs(1−αs)β >
β−(µ+d)
αsβ
, since
β − (µ+ d)
2αsβ
+
µ+ kαsd
2αs(1− αs)β −
β − (µ+ d)
αsβ
=
µ+ kαsd− (1− αs)[β − (µ+ d)]
2αs(1− αs)β
>
µ+ kαsd− (1− αs)[ µ+d1−kαs − (µ+ d)]
2αs(1− αs)β
=
(2− αs − 1−αs1−kαs )µ+ kαs(1− 1−αs1−kαs )d
2αs(1− αs)β > 0.
Therefore F (β−(µ+d)
αsβ
) > 0 implies no solution of F (p) = 0 over
(
β−(µ+d)− r−µ
d
αsβ
, β−(µ+d)
αsβ
)
,
because F (p) is decreasing over
(
β−(µ+d)− r−µ
d
αsβ
, β−(µ+d)
αsβ
)
.
Together if β > µ + d and r > µ, a unique solution of F (p) = 0 exists over(
β−(µ+d)− r−µ
d
αsβ
, β−(µ+d)
αsβ
)
when R0 > 1 and i
∗ < r−µ
d
and no solution exists over
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(
β−(µ+d)− r−µ
d
αsβ
, β−(µ+d)
αsβ
)
when R0 < 1 or i
∗ > r−µ
d
.
Because of the complexity of the expressions, we will not express the positive
steady state explicitly. Now assume that R0 > 1 and i
∗ < r−µ
d
. The Jacobian matrix
for a positive steady state can be expressed as:
J =
[−µ− (1− αs)βi∗ −[(1− αs)β − d]p∗ rK (−k + p∗)−αsβi∗ −(β − d)i∗ rK i∗
0 −dN∗ − r
K
N∗
]
. The study of the eigen-
values may be continued in future, for corresponding stability results.
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APPENDIX D
ADDITIONAL SIMULATION RESULTS
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Figure D.1: Blue color corresponds to model with constant entrance rate. Red color
corresponds to model with linear entrance rate. Black color corresponds to model
with linear entrance rate.
Table D.1: Baseline parameter values generated from data fitting
constant entrance linear entrance logistic entrance initial guess
β 0.196924711 0.196935536 0.196924711 1− (1− 0.0038)80
≈ 0.26256628106
µ 0.029793556 2.93E-02 0.02438153 1/35
≈ 0.028571428571429
d 0.119146121 0.11955454 0.125 1/10 = 0.1
Λ 996344 fixed value
calculated from data
r 0.04095 0.0511875 fixed value
or initial guess 0.04095
K 1.13E+08 9.00E+07
(Figure (A.1))
err 0.044056109 0.044755966 0.043080597
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Effectiveness indicators (k=0.2, α
s
=0.5)
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Figure D.2: For each simulation, models with different entrance rates use the cor-
responding parameter values from outfitting(see Table D.1). Blue color corresponds
to model with constant entrance rate. Red color corresponds to model with linear
entrance rate. Black color corresponds to model with linear entrance rate. Notice
that for models with linear entrance rate and logistic entrance rate, some indicators
are not well defined and can have negative values which are not shown in the figures.
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